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Epilepsy affects 50 million people world-wide. Since 1982, the Western Infirmary 
Epilepsy Unit has provided a specialist service for over 6900 people with suspected 
and established seizure disorders. The twelve studies detailed in this thesis discuss the 
management of epilepsy in different patient populations, and explore beneficial and 
adverse effects of antiepileptic drugs (AEDs). 
 
AED development has allowed advances in pharmacological treatment of localisation-
related epilepsies. Thus, outcomes were investigated in 550 such patients followed-up 
at the epilepsy clinic over 13 years (Paper i). Of these, 312 (57%) became seizure-free 
on medication. Those with hippocampal sclerosis had the poorest outcome (p<0.01), 
and a higher incidence of febrile convulsions (p<0.001). Although many patients 
benefited from AED therapy, results may be biased, given this cross-sectional study 
analysed data from both newly diagnosed patients, and those with drug-resistant 
seizures.  
 
Many people with epilepsy take more than one AED, although supportive evidence is 
sparse. Hence, polytherapy outcomes in 2881 patients registered with the Epilepsy 
Unit database were examined (Paper ii). Of these, 1617 (56%) were seizure-free, with 
332 (21%) taking more than one AED (287 on two, 86%; 42 on three, 13%; 3 on four, 
1%). There were 40 duotherapy and 28 triple therapy combinations resulting in 
seizure freedom. Therefore, combining two or three, but rarely four AEDs may be 
useful for patients not responding to monotherapy. Because this was a retrospective 
analysis of newly treated patients and those with refractory epilepsy, the analysis was 
subject to bias. Lack of a control group was also a weakness. Epilepsy Unit staff are 
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therefore now examining similar outcomes in a large population of newly treated 
patients only. 
 
To establish the place of recently marketed AEDs in clinical practice, four studies 
examined prospectively the efficacy and tolerability of the novel agent, topiramate, in 
uncontrolled epilepsy. Adjunctive topiramate was administered in 170 patients with 
refractory seizures (Paper iii). Seizure frequency and adverse events were monitored. 
Patients were followed-up until seizure freedom for ≥ 6 months, ≥ 50% or <50% 
seizure reduction, intolerable side-effects, or lack of efficacy occurred. Seizure 
freedom was achieved in 39 (23%) patients. A ≥50% reduction in seizure frequency 
was reported in 80 (47%) others. Doses were often lower than those in regulatory 
studies. Efficacy as monotherapy was also demonstrated. Using the same end-points, 
topiramate was added to AED regimens of 64 patients with learning disabilities and 
epilepsy (Paper iv). Remission from seizures was established in 16 (25%).  
 
In similar fashion, levetiracetam was started in 156 patients with uncontrolled 
epilepsy (Paper v).  Of these, 40 (26%) became seizure-free, many on low doses. 
When the drug was added to AED regimens in 64 patients with learning disabilities, 
24 (38%) became seizure-free for at least 6 months (Paper vi). Caregiver quality-of-
life scores improved significantly with levetiracetam (p<0.001). It is important to 
recognise that for all four audits results may be biased due to their observational 
nature, and the fact that they were undertaken at a single centre, with no control 
group. For patients with learning disabilities, small numbers, and retrospective 
baseline recordings for some could also have introduced bias. 
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In Papers vii, viii and ix, findings from longitudinal studies in teenagers, people with 
learning disabilities and epilepsy, and newly diagnosed elderly patients attending the 
Epilepsy Unit, are reported. At the Teenager Clinic, 301 adolescents were reviewed 
over four years (Paper vii). Epilepsy was excluded in 135 (45%), five taking AEDs. A 
single seizure occurred in 22 others. In the 144 with epilepsy, seizure freedom for ≥ 
12 months was attained in 76 (53%), but outcomes were poorer than expected. 
Neuroimaging was abnormal in 27 (43%). Newly diagnosed patients fared better than 
those taking treatment (p<0.05). More teenagers with primary generalised seizures 
(60%) attained remission, compared to those with focal-onset seizures (46%) 
(p<0.02). The retrospective natures of the analysis, and lack of control group may 
have biased results, thus making statistical conclusions inaccurate. Findings suggested 
the need for improved services. 
 
Over four years, 214 patients with learning disabilities and refractory epilepsy were 
followed-up (Paper viii). Although it is generally thought these individuals’ seizures 
are difficult to control, 59 (43%) became seizure-free for ≥ 12 months with AEDs. 
There was no change in quality-of-life scoring during this time, and no relationship 
between extent of learning disability and seizure control. The observational nature of 
the audit, and lack of control group may have biased results. 
 
Currently, there are few data on elderly people with epilepsy. Thus, outcomes over a 
20-year period in 117 newly diagnosed senior citizens were examined (Paper ix). 
After starting AED treatment, 93 (79%) became seizure-free for ≥ 12 months, 73 
(62%) with their first drug. Prognosis was better than in younger patients, and for 
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those with fewer pre-treatment seizures (p=0.0078). Again bias may have been 
introduced because of the study’s observational nature and lack of control group. 
 
The final studies concentrate on AED-related adverse effects (Papers x, xi and xii). 
Bone changes have been reported with AED use. Hence, the relationship between 
bone mineral density, and long-term AED treatment in 78 older adults (47 post-
menopausal women, 31 men), taking hepatic enzyme-inducing or non-inducing 
AEDs, was explored in a case-controlled study (Paper x). Men had significantly lower 
bone mineral density than controls at the lumbar spine (p<0.01), and neck of femur 
(p<0.005). Women had statistically reduced bone mineral density at the femoral neck 
(p<0.05). It was concluded that long-term AED treatment is an independent risk factor 
for reduced bone mineral density in people with epilepsy. 
 
As sodium valproate may be associated with metabolic changes and polycystic 
ovarian syndrome, hormone profiles were compared in 76 young men and women 
taking sodium valproate or lamotrigine monotherapy, to assess whether a 
pharmacological effect of valproate was responsible (Paper xi). Results revealed only 
four obese females exhibiting biochemical characteristics of polycystic ovarian 
syndrome (p=0.05), with obese patients of both sexes (p=0.01), and valproate-treated 
men (p=0.03) having higher insulin concentrations. Results are not significant when 
corrected for multiple comparisons. It can therefore be concluded that no differences 
in metabolic indices between patients taking sodium valproate or lamotrigine existed.     
 
To examine further effects on androgenic hormones, and the efficacy and tolerability 
of sodium valproate and lamotrigine monotherapy, a randomised, prospective study in 
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225 patients was performed (Paper xii). Patients were recruited if they presented with 
a minimum of two unprovoked seizures of any type, or a single seizure and 
underlying neuropathology. Of patients with partial-onset seizures, 81 received 
sodium valproate and 80 were randomised to receive lamotrigine. Of those with 
idiopathic generalised epilepsies, 30 received sodium valproate and 34 took 
lamotrigine. Seizure-free rates were identical in both arms at twelve months between 
the valproate and lamotrigine cohorts. There was a trend towards superiority for 
valproate (57% seizure-free) over lamotrigine (35% seizure-free) for patients with 
idiopathic generalised epilepsies (p=0.09), but a converse separation of outcomes for 
localisation-related epilepsies (43% seizure-free with valproate, 53% seizure-free with 
lamotrigine, p=0.24). More patients taking sodium valproate withdrew due to adverse 
events (p=0.046), eight because of weight gain. Neither drug altered testosterone, sex-
hormone binding globulin, and androstenedione concentrations, or changed the free 
androgen index, at six and twelve months, but lack of further formal monitoring may 
have biased results. 
 
These studies report results from different patient populations, including those with 
refractory epilepsy. Successful pharmacological outcomes were achieved in people 
with localisation-related epilepsies, and those taking polytherapy.  Patients with 
learning disabilities and elderly individuals fared better than expected, although 
results were disappointing in adolescents. AEDs, can, however, be associated with 
adverse effects, and data show how certain patients may require screening for such 
changes, and/or avoidance of certain drugs. These findings have to be considered in 
the context that the design of several of the projects may have introduced inherent 
bias. 
 17
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 1. Introduction 
Antiepileptic drugs (AEDs) are the mainstay of treatment for people with epilepsy. In 
the last twenty years, there has been an explosion in novel agents, affording greater 
opportunities for therapeutic strategies, and the attainment of seizure freedom. At the 
Epilepsy Unit, in the Western Infirmary, Glasgow, a specialist clinical service for 
people with suspected and established seizure disorders has been running since 1982. 
There are now over 6900 patients registered with the service. This thesis centres on 12 
publications, in which outcome data were derived from different patient populations 
studied by the author and associated Epilepsy Unit staff. 
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2. History of antiepileptic drug treatment 
Epilepsy affects around 50 million people globally, with an annual incidence of 50-70 
cases per 100,000 of the population (Hauser et al, 1996). Epilepsy is derived from 
‘epilambanein’, the ancient Greek word which means ‘to seize’ or ‘to attack’. The 
history of the condition and its treatment can be traced back 4000 years (Gross, 1992). 
Details can be found in classical Chinese medical texts dating from 770 to 221 BC. 
Hippocrates called epilepsy the ‘Sacred Disease’ (Lebrun, 1992), and hypothesised 
that seizures were due to an overflow of phlegm from the brain. Early therapies were 
often derived from animals and plants. Such treatments included tortoise blood, 
genitals of seals or hare, hippopotamus, boar, ram and cock testicles. It was not until 
the mid 19th century, that Robert Bentley Todd and John Hughlings Jackson 
developed the first electrical theories of epilepsy (Reynolds, 2001). The anti-seizure 
properties of potassium bromide were beginning to be recognised around this time 
(Locock, 1857) and, although side-effects such as rash were common, its efficacy 
earned it a place in history as the first AED (Figure 1, page 21).  
 
In 1911, the anticonvulsant properties of phenobarbital were discovered accidentally 
by Alfred Hauptmann (Hauptmann, 1912). Diphenylhydantoin was introduced by 
Merritt and Putman 27 years later (Merritt and Putnam, 1938).  This was followed by 
primidone, ethosuximide, benzodiazepines, carbamazepine and, in 1973, valproic 
acid. After a 16-year gap, vigabatrin, the first of the newer AEDs, was licensed. This 
heralded the influx of thirteen more agents, with others to follow. Together with 
modern imaging techniques, these drugs have revolutionised the medical management 
of people with epilepsy. 
 Oxcarbazepine
Figure 1. Chronology of antiepileptic drug development in the United Kingdom
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3. Managing patients with newly diagnosed epilepsy 
3.1  Diagnosis and investigation 
The onset of seizures can be terrifying, and has the potential to turn an individual’s 
life upside-down. Optimal management is the key to obtaining the best outcome. An 
adult who is suspected to have had a first seizure should be referred to an epilepsy 
specialist for rapid assessment (SIGN, 2003). Diagnosis is based on the history, 
ideally from a witness. Partial (focal-onset) seizures can have many varied 
presentations from a brief sensory, autonomic or motor disturbance, to confusion and 
aggression lasting several minutes. Post-ictal symptoms and signs such as exhaustion, 
headache, muscle pain and Todd’s paresis can provide useful clues if there is 
diagnostic difficulty. Tonic-clonic seizures usually have a more clear-cut presentation 
and may herald the onset of epilepsy. Given this scenario, it is worth asking about 
focal events, absence seizures and myoclonic jerks. These may have been occurring 
for many years, without a diagnosis having been made.  
 
Magnetic resonance imaging (MRI) is the current standard of reference for people 
with seizure activity (NICE, 2004). Lesions detected have implications for prognosis 
and future management. Although computerised tomographic (CT) scanning can be 
useful in the urgent assessment of seizures, or where MRI is contraindicated, this tool 
is not sensitive enough to detect pathologies such as subtle cortical dysplasias and 
hippocampal sclerosis (Commission on Neuroimaging, ILAE, 1998).  
 
Electroencephalography (EEG) is useful in supporting the classification of epileptic 
seizures and syndromes. The investigation can detect a photoparoxysmal response 
22 
which is present in around 5% of epilepsies, and generally has a favourable prognosis  
(Verrotti, 2004). A single routine EEG recording will show definite epileptiform 
abnormalities in 29-38% of adults who have epilepsy, rising to 69-77% with repeated 
recordings (SIGN, 2003). Sensitivity can also be increased with sleep deprivation 
(Leach et al, 2006). It is essential, also, to ensure that long QT syndrome, which can 
present with a seizure, is excluded by obtaining a routine electrocardiogram (Dunn et 
al, 2005). Together with a comprehensive history from a witness, information 
obtained from neuroimaging and EEG can help to classify the seizure type or 
syndrome. 
 
3.2 Classification of seizure types and syndromes 
Current classification of seizure type was defined by the International League Against 
Epilepsy (ILAE) in 1981 (Table 1, page 24), according to the clinical description of 
the event, as well as the EEG pattern (Commission on Classification and 
Terminology, ILAE, 1981).  Partial seizures are those in which the first clinical and 
EEG signs indicate initial neuronal activation limited to part of one cerebral 
hemisphere. If consciousness is not impaired, the seizure is termed simple partial, 
whereas if consciousness is impaired, the event is classified as being a complex partial 
seizure. If the focal discharge propagates to both hemispheres, the seizure becomes 
secondary generalised. These may be tonic-clonic, or more rarely tonic, or clonic in 
type. Where a generalised seizure occurs without any clinical or electrophysiological 
evidence for a focal onset, the seizures, which involve both hemispheres 
simultaneously, may be convulsive or non-convulsive, and include absence, tonic-
clonic, myoclonic, clonic, tonic, and atonic seizures.  
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Table 1. International classification of seizure types  
(Commission on Classification and Terminology, ILAE, 1981) 
Seizure Types 
 
Features 
 
Partial Seizures 
Simple Partial Seizures 
- With motor symptoms 
    - Focal motor 
    - Focal motor march (Jacksonian) 
    - Versive 
    - Postural 
    - Phonatory 
 
- With somatosensory or special sensory 
symptoms 
    - Somatosensory 
    - Visual 
    - Olfactory 
    - Gustatory 
    - Vertiginous 
 
With autonomic signs or symptoms 
 
With psychic symptoms 
 
Complex Partial Seizures 
 
 
Partial Seizures evolving to Secondary 
Generalised Seizures 
EEG findings suggest focal onset 
Consciousness not impaired 
 
 
 
 
 
Vocalisation arrest of speech 
 
Simple hallucinations 
 
 
 
 
 
 
 
Epigastric sensations, pallor, sweating, 
flushing, piloerection, papillary dilation 
 
 
Disturbance of higher cortical function. 
Consciousness impaired 
 
EEG discharges rapidly generalise 
Absence Seizures 
Typical absence 
 
Atypical absence 
 
Regular and symmetrical 3-Hz spike-
wave complex on EEG 
Irregular slow spike-wave complex on 
EEG 
Myoclonic Seizures Polyspike or slow spike-wave complex 
on EEG 
Clonic Seizures Fast activity or slow spike-wave complex 
on EEG 
Tonic Seizures Low-voltage fast EEG 
Tonic-Clonic Seizures Rhythm of less than 10Hz on EEG 
Atonic Seizures Polyspike-wave complex or low voltage 
fast wave on EEG 
Unclassified Seizures  
 
EEG; Electroencephalogram 
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The ILAE Commission on Classification and Terminology has defined an epilepsy 
syndrome as ‘a complex of signs and symptoms that define a unique epilepsy 
condition.’ These include items such as seizure type, anatomy, precipitating factors, 
age of onset, severity, chronicity, diurnal and circadian rhythm, and sometimes 
prognosis (Table 2, page 27) (ILAE Commission on Classification and Terminology, 
1989).  Syndromes should be distinguished from epileptic diseases which are defined 
as ‘pathologic conditions with a single, specific, well-defined aetiology’.  
 
Within the 1989 classification system, two key axes were defined, one for generalised 
versus localisation-related conditions and another for aetiology (symptomatic, 
idiopathic, and cryptogenic). Generalised seizures are defined traditionally as those 
which involve both cerebral hemispheres simultaneously and symmetrically during 
the actual seizure. Localisation-related (focal-onset) seizures arise from a discrete, 
lateralised region, usually in the cerebral cortex, regardless of later spread. There are, 
however, syndromes such as Landau-Kleffner and Dravet syndrome in which both 
focal and generalised features occur.  
 
‘Symptomatic’ seizures can be thought of as those which have a preceding, non-acute 
insult or condition, such as stroke, head trauma and intracranial infection, the 
occurrence of which has been demonstrated to be associated with an increased risk of 
epilepsy (Hauser et al, 1993). Over 80 conditions are implicated (Engel, 2001). 
‘Idiopathic’ was originally used to refer to seizures which were not symptomatic, but 
this definition now is used for well-characterised forms of epilepsy, mainly occurring 
in childhood and adolescence, and believed (though not always demonstrated) to have 
a genetic basis. The definition of ‘cryptogenic’ has changed throughout the years, but 
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now generally refers to epilepsies which do not fit the criteria for idiopathic 
conditions or have a remote symptomatic cause. Classification systems have been 
considered throughout the years (Engel, 2001; Engel, 2006), and revision is underway 
(ILAE Commission on Classification and Terminology, 2005-2009, in press).  
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Table 2.  International classification of epilepsies and epileptic syndromes 
(Commission on Classification and Terminology, ILAE, 1989) 
Localisation-related (focal, local, or partial) 
Idiopathic epilepsy with age-related onset 
- benign childhood epilepsy with centrotemporal spikes (benign rolandic epilepsy) 
- childhood epilepsy with occipital paroxysms 
- primary reading epilepsy 
Symptomatic epilepsy 
Cryptogenic epilepsy 
Generalised 
Idiopathic epilepsy with age-related onset (listed in order of age at onset) 
- benign neonatal familial convulsions 
- benign neonatal non-familial convulsions 
- benign myoclonic epilepsy in infancy 
- childhood absence epilepsy 
- juvenile absence epilepsy 
- juvenile myoclonic epilepsy 
- epilepsy with generalised tonic-clonic seizures on awakening 
- other idiopathic epilepsies 
Cryptogenic or symptomatic epilepsy (listed in order of age at onset) 
- West syndrome (infantile spasms) 
- Lennox Gastaut syndrome (childhood epileptic encephalopathy) 
- epilepsy with myoclonic-astatic seizures 
- epilepsy with myoclonic absence seizures 
Symptomatic epilepsy 
- Non-specific syndromes (early myoclonic encephalopathy, early infantile epileptic 
encephalopathy) 
- Specific syndromes (epileptic seizures as a complication of a disease, such as 
phenylketonuria, juvenile Gaucher’s disease or Lundborg’s progressive myoclonic 
epilepsy) 
Epilepsies undetermined whether focal or generalised 
With both generalised and focal features 
- neonatal seizures 
- severe myoclonic epilepsy in infancy 
- epilepsy with continuous spike waves during slow-wave sleep 
- acquired epileptic aphasia (Landau-Kleffner syndrome) 
- without unequivocal generalised or focal features* 
Special syndromes 
Situation-related seizures 
- febrile convulsions 
- seizures related to other identifiable situations, such as stress, hormonal changes,  
drugs, alcohol withdrawal or sleep deprivation 
Isolated, apparently unprovoked epileptic events 
Epilepsies characterised by specific modes of seizure precipitation 
Chronic progressive epilepsia partialis continua of childhood 
 
* Includes cases in which the clinical and electroencephalographic findings do not 
permit classification of the epilepsy as clearly generalised or localisation-related, such 
as cases of tonic-clonic seizures during sleep. 
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Once classification has been decided upon (where possible), this leads to the question 
of how best to treat the particular seizure type(s) or syndrome. With the growing 
number of AEDS available, it is important to have a solid evidence base to guide 
clinicians in the most appropriate use of rational AED regimens. This evidence base 
takes the form of randomised, controlled trials (RCTs), systematic reviews and meta-
analyses, and pragmatic studies. 
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4. Establishing the evidence base for the use of antiepileptic drugs 
4.1 Randomised controlled trials 
Regulatory authorities require proof of efficacy and safety before a licence for a new 
AED can be granted. When assessing the benefits and drawbacks of such health-
related interventions, RCTs are considered the gold standard. Subsequent systematic 
reviews and meta-analyses may provide further information. As outlined in the 
CONSORT statement, a properly conducted RCT will minimise the risk of bias and 
will answer a specific question the study has been designed to examine (CONSORT 
Group, 2007). Adequate concealment methods of randomisation comprise central 
randomisation, numbered coded vehicles; and opaque, sealed, and sequentially 
numbered envelopes (Pildal et al, 2005). Blinding minimises bias further, with single 
blind studies in which patients are unaware of their treatment, double blind studies, 
where neither the patient, nor the clinician know the treatment, and triple blind 
studies, where neither patients, clinicians, nor those conducting the analysis are aware 
of treatment allocation. A rigorous RCT will include patients who are as similar as 
possible, and will exclude patients who receive additional treatments or who have co-
morbid conditions, as these confounding factors may invalidate results. Bias is 
minimised where outcomes are fully, as opposed to selectively, reported.  
 
When a pharmaceutical company initially plans to market an AED, it usually 
undertakes an RCT in the form of an add-on study, investigating a range of doses 
versus placebo in patients with refractory epilepsy. The aim is to show a clinically  
useful dose-response relationship, ideally including a non-effective dose, which will 
help identify the effective dosage range. The design of choice is that of a parallel-
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group study, where patients are randomised to receive one of several doses of drug or 
matched placebo. Cross-over studies, where the patient receives the active drug and 
placebo in two separate phases, separated by a washout period, are considered less 
rigorous because there may be carry over effects during the washout period. There are 
also ethical and maintained consent issues, as any benefit obtained during the first 
period will be lost in the second. As monotherapy, the study drug can be compared to 
standard doses of an established AED in an active-control study. Patients participating 
in conversion to monotherapy studies receive active drug or control. The original 
AEDs are then tapered off and patients maintained, if possible, on the new 
monotherapy.  
 
To minimise bias in RCTs, patients participating are usually highly selected, within a 
desired age range, and often with very refractory epilepsy. Those who are poorly 
adherent or who have comorbidities may be excluded. Compliance is strictly 
monitored, with close and frequent follow up, often different to that of the routine 
epilepsy clinic. There is generally a fixed number of patients recruited, and a fixed 
duration of treatment. Women of child-bearing age may be excluded if pregnancy is 
an issue, given that the human teratogenic potential of new AEDs is undetermined. 
The aim of these studies for European regulatory purposes, is to show equivalence of 
the new drug to the standard comparator; and for American regulatory purposes, to 
show superiority over the comparator.  
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4.2 Pragmatic studies of antiepileptic drugs 
Taking the pros and cons of RCTs into account, how can other data regarding AED 
use be acquired? Although RCTs performed for regulatory purposes provide 
important data on specific issues, they are not a reflection of routine clinical practice.  
As such, RCTs do not provide the best evidence on flexible dosing schedules, chronic 
adverse effects, idiosyncratic reactions, or teratogenicity, and thus do not always 
provide information required for everyday decision making (Chadwick and Marson, 
2007). Once an AED is licensed, it is important, therefore, to continue studying its 
effects through more pragmatic research in the clinical setting. There has been a call 
in recent months for improved observational studies. The CONSORT statement has 
recently been extended to guide clinicians on undertaking ‘pragmatic’ as opposed to 
’explanatory’ trials (Zwarenstein et al, 2008), where ‘pragmatic’ describes studies 
designed to help choose between options for healthcare, and ‘explanatory’ describes 
trials designed to test causal research hypotheses (Schwartz and Lellouch, 1967). This 
has been backed by the STROBE (Strengthening the Reporting of Observational 
Studies in Epidemiology) statement, a checklist of items which should be addressed in 
articles reporting cohort, case-control, and other observational studies (von Elm et al, 
2007).  
 
Cohort studies, which can be prospective or retrospective, are designed to answer 
questions of the type ‘What are the effects of this exposure?’. A group of people with 
a particular exposure are compared with another group who either have not had the 
exposure, or have had a different level of exposure. Case-control studies are designed 
to answer the question ‘What are the factors that caused this event?’. Individuals with 
an outcome are compared with other individuals from the same population who do not 
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have the outcome. Case-control design is generally used to assess the causes of a new 
problem, but may also be useful for the evaluation of population-based interventions 
such as screening. In the clinical setting, it can also be helpful to monitor the 
outcomes of an intervention, such as the addition of a new AED, in order to become 
familiar with its dosing and effects. The limitation of such observational research has 
to be recognised, however, as without randomisation, a control group, and exclusion 
of confounding factors, inherent bias occurs.  
 
4.3 Research and audit – ethical issues 
In an ideal world, ethical consideration should apply to all areas of medicine (Wade, 
2005). Ethics committees are required to examine all research proposals, but most 
now exclude projects they consider to be audit. It is therefore important to 
differentiate between research and audit, although the distinction between the two is 
often not clear cut. Research has been defined as ‘a systematic investigation 
undertaken to discover facts or relationships and reach conclusions using scientifically 
sound methods’ (Hockey, 1996). Clinical audit is ‘a quality improvement process that 
seeks to improve patient care and outcomes through systematic review of care against 
explicit criteria and the implementation of change’ (NICE, 2007).  
 
Research and audit are similar in many ways. Both start by posing a question, can be 
undertaken prospectively or retrospectively, involve careful sampling, questionnaire 
design and analysis of findings, and both activities should be professionally led. There 
are, however, a number of differences between research and audit (National Research 
Ethics Service, 2008), and these are summarised in Table 3 (page 34). Given this 
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information, it can be argued that some of the studies contained in this thesis can be 
classified as audit, whilst others fall into the category of research. The reasons for this 
are discussed in relation to each relevant publication in Chapters 6, 7, 8 and 9. For 
people with epilepsy, many of whom require to take long-term AED treatment, 
outcomes from research and audit projects provide crucial data informing on the 
diagnosis, investigation, treatment, and outcomes of the condition.  
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Table 3. Differences between audit and research – ethical considerations 
(National Research Ethics Service, 2008) 
Research Clinical Audit 
The attempt to derive generalisable new 
knowledge, including studies that aim to 
generate hypotheses, as well as studies 
that aim to test them. 
Designed and conducted to produce 
information to inform delivery of best 
care. 
Quantitative research – designed to test a 
hypothesis. 
Qualitative research – identifies/explores 
themes following established 
methodology. 
Designed to answer the question: ‘Does 
this service reach a predetermined 
standard?’ 
Addresses clearly defined questions, aims 
and objectives. 
Measures against a standard. 
Quantitative research – may involve 
evaluating or comparing interventions, 
particularly new ones. 
Qualitative research – usually involves 
studying how interventions and 
relationships are experienced. 
Involves an intervention in use ONLY 
(the choice of treatment is that of the 
clinician and patient, according to 
guidance, professional standards and/or 
patient preference). 
Usually involves collecting data that are 
additional to those for routine care, but 
may include data collected routinely. 
May involve treatments, samples or 
investigations additional to routine care. 
Usually involves analysis of existing 
data, but may include administration of 
simple interview or questionnaire. 
Quantitative research – study design may 
involve allocating patients to intervention 
groups. 
Qualitative research uses a clearly 
defined sampling framework underpinned 
by conceptual theoretical justifications. 
No allocation to intervention groups: the 
healthcare professional and patient have 
chosen the intervention before the clinical 
audit. 
May involve randomisation. No randomisation. 
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5. Rational antiepileptic drug monotherapy in adults 
The decision to start AED treatment can be based on several criteria including the 
likelihood of seizure recurrence, the consequences of continuing seizures for the 
patient, and the beneficial and adverse effects of the pharmacological agent chosen 
(NICE, 2004). Risk of recurrence can vary depending on the seizure type or 
syndrome. Patients with epileptiform discharges on the EEG or congenital 
neurological defects are at high risk (up to 90%) of further seizures. Risk is also 
increased in people with symptomatic seizures, in those with cerebral lesions, and in 
patients with Todd’s paralysis. 
 
When considering whether or not to treat a first seizure, it is important to take into 
account the patient’s views of the situation, as well as those of their family. To this 
end, it is vital that everyone concerned is provided with a clear explanation of events, 
and the likely consequences. For people who are anxious not to have another seizure, 
early introduction of treatment may be best. Further seizure activity may be 
unacceptable for those who need to drive, continue in employment, or are responsible 
for vulnerable family members. Those with a family history of epilepsy may be more 
inclined to accept long-term treatment. Occasionally, a person will have a relative 
who has succumbed to a seizure-related death and will, therefore, gain peace-of-mind 
by starting medication. At the opposite end of the spectrum, some patients will choose 
not to start treatment, even after a number of seizures, because they dislike taking 
medication. Others may have a problem with the stigma of the diagnosis of epilepsy, 
and all this entails. Treatment may be difficult in people who abuse drugs or alcohol, 
or who are unwilling or unlikely to take medication. These individuals should be 
counselled appropriately and be made aware of the implications of further seizure 
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activity, including the risk of sudden unexpected death in epilepsy (SUDEP) 
(Mohanraj et al, 2006).   
 
When starting treatment, AED monotherapy is associated with better compliance and 
fewer side effects than combination regimens. As 60% of people will gain control of 
their epilepsy with the first or second AED, much attention should be given to the 
selection of initial drug, taking into account the efficacy of the AED for the seizure 
type or syndrome (Kwan and Brodie, 2000a).  
 
5.1 Evidence-based guidelines 
The number of available AEDs has increased rapidly in the last 20 years, giving more 
choice when initiating therapy. Major evidence-based guidelines have been developed 
during this time, assisting clinicians and patients in making appropriate treatment 
choices. These include the United Kingdom (UK) guidelines issued by the National 
Institute for Clinical Excellence (NICE) - ‘The diagnosis and management of the 
epilepsies in adults and children in primary and secondary care’ (NICE, 2004), the 
Scottish Intercollegiate Guidelines Network (SIGN) ‘Diagnosis and management of 
epilepsy in adults’ (SIGN, 2003), and ‘Diagnosis and management of epilepsies in 
children and young people’ (SIGN, 2005), the American Academy of Neurology / 
American Epilepsy Society Guidelines on treatment of new-onset epilepsy (American 
Academy of Neurology, 2004), and those compiled by the International League 
Against Epilepsy (Glauser et al, 2006). These guidelines are based on the ‘best 
available evidence’, but may not be a substitute for knowledge, skill, and experience 
in managing the individual patient.  
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5.2 Treatment goals 
The goal of AED treatment should be complete seizure control without, or with 
minimal adverse effects. AED monotherapy is associated with better compliance, 
fewer adverse effects, fewer drug interactions, and less teratogenic potential, as well 
as being more cost-effective (Devinsky and Cramer, 2000). The drug of choice should 
have efficacy for the given seizure type or syndrome, with other important properties 
comprising safety, tolerability, pharmacokinetic properties, and formulation. Selecting 
the most suitable AED also requires detailed knowledge about the patient’s medical 
and drug history, and their social circumstances. 
 
 
5.3 Efficacy 
The profile of activity against different seizure types and syndromes varies among 
AEDs (Table 4, page 38). Classification is therefore of paramount importance. Certain 
epilepsy syndromes have been found to be particularly responsive to specific agents. 
For example, juvenile myoclonic epilepsy (JME) responds well to sodium valproate 
(Sundqvist et al, 1998), and vigabatrin is regarded by many as the treatment of choice 
for infantile spasms secondary to tuberous sclerosis (Elterman et al, 2001). 
Conversely, narrow spectrum drugs such as carbamazepine (Liporace et al, 1994), 
phenytoin (Duarte et al, 1996), gabapentin (Ascapone, 2000) and oxcarbazepine 
(Gelisse et al, 2004) can worsen myoclonic jerks, and absence seizures. AED 
treatment of common epilepsy syndromes presenting in adulthood is discussed further 
in Chapter 6. 
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Table 4. Efficacy of antiepileptic drugs against common seizure types and syndromes 
Antiepileptic Drug Focal-
onset 
seizures 
Primary generalised seizures Lennox 
Gastaut 
Infantile 
Spasms 
  Tonic 
clonic 
Absence Myoclonic   
Carbamazepine + + ↓ ↓ 0 0 
Phenytoin + + ↓ ↓ 0 0 
Phenobarbital + + + 0 ? ? 
Primidone + + 0 ? ? ? 
Ethosuximide 0 0 + 0 0 0 
Sodium valproate + + + + + + 
Clobazam + + ? + + ?+ 
Clonazepam + + ? + ?+ ?+ 
Vigabatrin + ?+ ↓ ↓ ? + 
Lamotrigine + + + +* + ?+ 
Gabapentin + ?+ ↓ ↓ ? ? 
Topiramate + + ? + + ? 
Tiagabine + ? ↓ ? ? ?+ 
Oxcarbazepine + + ↓ ↓ 0 0 
Levetiracetam + + ?+ + ? ? 
Pregabalin + ? ? ? ? ? 
Stiripentol + + ?+ + ?+ ?+ 
Zonisamide + ?+ ?+ ?+ ?+ ?+ 
Rufinamide + + ?+ ?+ + ? 
Lacosamide + ? ? ? ? ? 
 
+ proven efficacy; ?+ probable efficacy; 0 ineffective; ↓ worsens control; ? unknown 
*Lamotrigine may worsen myoclonic seizures in some patients 
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AEDs currently licensed for use as monotherapy in the UK comprise carbamazepine, 
phenytoin, phenobarbital, primidone, ethosuximide, sodium valproate, clobazam, 
clonazepam, lamotrigine, gabapentin, topiramate, oxcarbazepine, and levetiracetam. 
With the emergence of many new agents in recent years, there is a growing evidence 
base of studies (Tables 5 and 6, pages 40-43), and systematic reviews (Table 7, page 
44) comparing initial monotherapy treatments for different seizure types and 
syndromes. There is, however, currently no over-whelming efficacy evidence 
supporting use of a particular drug. This is due, principally to differences in study 
design, and the absence of thorough adverse effects data at equivalent dosage. There 
is a lack of properly conducted randomised, controlled trials, particularly for people 
with generalised tonic-clonic seizures. Recent data from the levetiracetam versus 
controlled-release carbamazepine trial suggested that most adults with newly 
diagnosed epilepsy will respond to a modest dose of any first line AED (Brodie et al, 
2007). The more pragmatic SANAD trials favoured lamotrigine over carbamazepine, 
gabapentin, topiramate, and oxcarbazepine for partial epilepsy (Marson et al, 2007a), 
and sodium valproate over lamotrigine or topiramate for generalised and 
unclassifiable epilepsy (Marson et al, 2007b).  
 
Table 5. Randomised controlled trials comparing antiepileptic drug (AED) monotherapies in patients with partial-onset seizures 
 
Reference AEDs compared Study Population Conclusions Comments 
Mikkelsen et  
al, 1981 
Carbamazepine 
Clonazepam 
36 adults with complex 
partial seizures 
No significant difference was found between the 2 drugs during 6 months’ treatment. Small cohorts 
Ramsay et al, 
1983 
Carbamazepine 
Phenytoin 
87 adults with  newly 
diagnosed partial-onset and 
primary GTCS 
Efficacy and tolerability were the same for both drugs. Double-blind study. 
Small patient numbers 
 Mattson et al, 
1985 
Carbamazepine 
Phenobarbital 
Phenytoin 
Primidone 
622 adults with partial and 
secondary generalised 
seizures 
 
Control of tonic-clonic seizures did not differ between the drugs. 
Carbamazepine more often controlled partial seizures compared to phenobarbitone or 
primidone. 
Primidone had efficacy similar to phenobarbital, but was tolerated less well. 
Multicentre study 
 Dam et al, 
1989 
Carbamazepine 
Oxcarbazepine 
235 adults with newly 
diagnosed partial-onset and 
primary GTCS 
No significant differences in efficacy were found between the two drugs. There was a 
trend towards better tolerability with oxcarbazepine 
Double-blind, 
multicentre study 
 Mattson et al, 
1992 
Carbamazepine 
Sodium valproate 
480 adults with complex 
partial or secondary GTCS 
Carbamazepine was superior to valproate in controlling complex partial seizures. 
Carbamazepine is as effective as sodium valproate in controlling secondary GTCS. 
Double-blind, 
multicentre study 
Richens et al, 
1994 
Carbamazepine 
Sodium valproate 
300 adults with newly 
diagnosed partial-onset or 
primary GTCS 
The drugs controlled seizures equally effectively. Significantly more patients 
continued on valproate than carbamazepine for at least 6 months. 
Open label study 
 Brodie et al, 
1995 
Carbamazepine 
Lamotrigine 
260 patients >13 years with 
untreated partial-onset or 
primary GTCS 
Similar efficacy results were obtained for both drugs. Lamotrigine was significantly 
better tolerated 
Double-blind, 
multicentre study 
 Christie et al, 
1997 
Oxcarbazepine 
Sodium valproate 
249 adults with partial or 
GTCS 
No significant differences in efficacy or tolerability found between the two drugs Double-blind, 
multicentre study 
 Bill et al, 1997 Phenytoin 
Oxcarbazepine 
287 adults with untreated 
partial-onset and primary 
GTCS 
No significant differences in efficacy found between the two drugs. 
Oxcarbazepine was significantly better tolerated than phenytoin 
Double-blind, 
multicentre study 
 Guerreiro et al, 
1997 
Phenytoin 
Oxcarbazepine 
193 children and adolescents 
with epilepsy 
No significant differences in efficacy found between the two drugs. Oxcarbazepine 
was tolerated and retained significantly better. 
Double-blind, 
multicentre study 
Chadwick et al, 
1998 
Gabapentin 300mg, 
900mg and 1800mg 
Carbamazepine 
292 patients aged 12-86 
years with newly diagnosed 
partial-onset seizures 
Gabapentin at 900mg or 1800mg/day is as effective and as safe as carbamazepine. Open label study. 
 Steiner et al, 
1999 
Phenytoin 
Lamotrigine 
181 newly diagnosed adults 
with partial-onset or primary 
GTCS 
Efficacy results were similar for the two drugs. There was a trend towards better 
tolerability with lamotrigine. 
Double-blind study. 
The high rash rate with 
lamotrigine was 
probably due to high 
starting doses 
Table 5 (continued) 
Reference AEDs compared Study Population Conclusions Comments 
Brodie et al, 
1999 
Carbamazepine 
Lamotrigine 
150 patients aged ≥65 years 
with newly diagnosed 
epilepsy 
No difference was found between the 2 drugs in time to first seizure. More patients 
continued with lamotrigine than with carbamazepine. 
Lamotrigine: 
carbamazepine 
treatment ratio was 2:1 
Chadwick, 
1999 
Carbamazepine 
Vigabatrin 
459 patients aged 12-65 
years with partial-onset 
seizures 
All efficacy outcomes favoured carbamazepine and failed to show equivalence 
between the two drugs. Time to first seizure was significantly greater with 
carbamazepine. Vigabatrin was associated with more psychiatric symptoms. 
Double-blind, 
multicentre study. 
 
 Brodie et al, 
2002 
Lamotrigine 
Gabapentin 
309 adults with partial-onset 
seizures or primary GTCS 
The drugs were similar in efficacy and tolerability Double blind, 
multicentre study 
 Privitera et al, 
2003 
Carbamazepine 
Sodium valproate 
Topiramate 
621 children and adults with 
newly diagnosed partial-
onset seizures or primary 
GTCS 
No significant differences in efficacy were found between the three drugs Double-blind, 
multicentre study 
Gilliam et al, 
2003 
Topiramate 50mg/d, 
200mg/d, or 500mg/d 
Patients aged ≥3 years with 
partial-onset seizures 
Seizure-free rates were significantly higher and time to first seizure was significantly 
longer with 200mg/d and 500mg/d 
Double-blind, 
multicentre study 
Arroyo et al, 
2005 
Topiramate 50mg/d, or 
400mg/d 
Patients ≥6 years old with 
untreated partial-onset or 
GTCS 
The higher dose was significantly more likely to produce seizure freedom than the 
lower dose. More patients on the higher dose discontinued treatment. 
Multicentre study 
 Rowan et al, 
2005 
Carbamazepine 
Lamotrigine 
Gabapentin 
593 patients aged ≥65 years 
with newly diagnosed 
epilepsy 
Seizure control outcomes were similar for the three drugs. Significantly more patients 
stopped carbamazepine due to adverse events compared to gabapentin and lamotrigine 
Double-blind, 
multicentre study 
 Brodie et al, 
2007 
Controlled release 
carbamazepine 
Levetiracetam 
579 patients ≥16 years with 
≥2 partial-onset or GTCS in 
the past year 
Seizure free rates were equivalent for both drugs Double-blind, 
multicentre study 
Marson et al, 
2007a 
 
Carbamazepine 
Gabapentin 
Lamotrigine 
Oxcarbazepine 
Topiramate 
1721 adults with partial-
onset seizures. 
For time to treatment failure, lamotrigine was significantly better tolerated than 
carbamazepine, gabapentin or topiramate. For time to 12-month remission, 
carbamazepine was significantly better tolerated than gabapentin. 
Multicentre 
study 
Marson et al, 
2007b 
Sodium valproate 
Lamotrigine 
Topiramate 
 
716 adults with newly 
diagnosed epilepsy 
Valproate was significantly better than topiramate in time to treatment failure. 
For patients with idiopathic generalised epilepsies, valproate had significantly better 
efficacy than topiramate or lamotrigine. Valproate was significantly better tolerated 
than topiramate. 
Multicentre 
study 
 Saetre et al, 
2007 
Controlled release 
carbamazepine 
Lamotrigine 
186 patients aged ≥65 years 
with newly diagnosed 
epilepsy 
Effectiveness was comparable for both drugs. 
There was a trend towards higher seizure free rates with carbamazepine and for better 
tolerability with lamotrigine. 
Double-blind, 
multicentre study 
GTCS; generalised tonic-clonic seizures 
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Table 6. Randomised controlled trials comparing antiepileptic drug (AED) monotherapies in patients with generalised tonic-clonic seizures (GTCS) 
 
Reference AEDs compared Study Population Conclusions Comments 
Shakir et al, 1981 Sodium valproate 
Phenytoin 
33 adults with epilepsy Sodium valproate was as effective as phenytoin Small cohort 
Turnbull et al, 1982 Phenytoin 
Sodium valproate 
88 adults with untreated 
partial-onset or primary GTCS 
No significant differences in efficacy between the drugs. 
Both were more effective for GTCS than partial seizures. 
 
Ramsay et al, 1983 Carbamazepine 
Phenytoin 
87 adults with  newly 
diagnosed partial-onset and 
primary GTCS 
Efficacy and tolerability were the same for both drugs. Small patient numbers 
Turnbull et al, 1985 Phenytoin 
Sodium valproate 
140 patients >16 years with 
partial or tonic-clonic seizures 
No significant differences in efficacy between the two 
drugs 
Single centre study 
Callaghan et al, 1985 Carbamazepine 
Phenytoin 
Sodium valproate 
181 adults with untreated 
epilepsy 
All the drugs were highly effective in controlling 
generalised seizures, but less effective in controlling partial 
seizures. 
Single centre study 
 Dam et al, 1989 Carbamazepine 
Oxcarbazepine 
235 adults with newly 
diagnosed partial-onset and 
primary GTCS 
No significant differences in efficacy were found between 
the two drugs. There was a trend towards better tolerability 
with oxcarbazepine 
Double-blind, multicentre 
study 
Aikia et el, 1992 Phenytoin 
Oxcarbazepine 
37 adult patients with newly 
diagnosed epilepsy.  
No significant differences in efficacy between the drugs. Single centre, double-
blind study. Small cohort 
Placencia et al, 1993 Carbamazepine 
Phenobarbital 
192 patients aged between 2 
and 60 years with 2 or more 
untreated seizures 
Both drugs had equal efficacy. Community-based study 
Richens et al, 1994 Carbamazepine 
Sodium valproate 
300 adults with newly 
diagnosed partial-onset or 
primary GTCS 
The drugs controlled seizures equally effectively. 
Significantly more patients continued on valproate than 
carbamazepine for at least 6 months. 
Multicentre, open label 
study 
Pulliainen et al, 1995 Carbamazepine 
Phenytoin 
43 adults with newly 
diagnosed partial-onset or 
primary GTCS 
No significant differences in efficacy between the drugs. Single centre, open label 
study 
Heller et al, 1995 Phenobarbital 
Phenytoin 
Carbamazepine 
Sodium valproate 
243 patients aged >16 years 
with untreated epilepsy 
No significant differences in efficacy between the drugs. 
More patients stopped phenobarbital due to side effects 
Two centre, randomised 
study 
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Table 6. (Continued) 
 
Reference AEDs compared Study Population Conclusions Comments 
Kalviainen et al, 1995 Carbamazepine 
Vigabatrin 
100 patients aged 15 to 64 
years with untreated epilepsy 
Significantly more patients remained seizure-free with 
carbamazepine than with vigabatrin. The former was 
withdrawn more often due to adverse effects. The latter was 
statistically more often stopped due to lack of efficacy. 
Single centre, open label 
study 
 Brodie et al, 1995 Carbamazepine 
Lamotrigine 
260 patients >13 years with 
untreated partial-onset or 
primary GTCS 
Similar efficacy results were obtained for both drugs. 
Lamotrigine was significantly better tolerated 
Double-blind, multicentre 
study 
Reunanen et al, 1996 Carbamazepine 
Lamotrigine 
343 patients >12 years with 
untreated partial or GTCS 
Carbamazepine and lamotrigine were equally efficacious, 
with a trend to better tolerability with lamotrigine. 
Multicentre 
randomised study 
 Bill et al, 1997 Phenytoin 
Oxcarbazepine 
287 adults with untreated 
partial-onset and primary 
GTCS 
No significant differences in efficacy between the drugs. 
Oxcarbazepine was significantly better tolerated than 
phenytoin 
Double-blind, multicentre 
study 
 Christie et al, 1997 
 
Oxcarbazepine 
Sodium valproate 
249 adults with partial or 
generalised seizures 
No significant differences in efficacy or tolerability found 
between the two drugs 
Double-blind, multicentre 
study 
 Steiner et al, 1999 Phenytoin 
Lamotrigine 
181 untreated adults with 
partial-onset or primary GTCS 
Efficacy results were similar for the two drugs. There was a 
trend towards better tolerability with lamotrigine. 
The high rash rate with 
lamotrigine was probably 
due to high starting doses 
 Brodie et al, 2002 Lamotrigine 
Gabapentin 
309 adults with partial-onset 
seizures or primary GTCS 
The drugs were similar in efficacy and tolerability Double blind, multicentre 
study 
 Privitera et al, 2003 Carbamazepine 
Sodium valproate 
Topiramate 
621 children and adults with 
newly diagnosed partial-onset 
seizures or primary GTCS 
No significant differences in efficacy were found between 
the three drugs 
 
Arroyo et al, 2005 Topiramate 50mg/d, 
or 400mg/d 
487 patients ≥6 years old with 
untreated partial-onset or 
GTCS 
The higher dose was significantly more likely to produce 
seizure freedom than the lower dose. More patients on the 
higher dose discontinued treatment. 
Double blind, multicentre 
study 
Marson et al, 2007a Sodium valproate 
Lamotrigine 
Topiramate 
 
716 adults with newly 
diagnosed epilepsy 
Valproate was significantly better than topiramate in time to 
treatment failure. 
For patients with IGEs, valproate had significantly better 
efficacy than topiramate or lamotrigine. Valproate was 
significantly better tolerated than topiramate. 
Multicentre, randomised 
study 
IGEs; Idiopathic generalised epilepsies 
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Table 7. Systematic reviews of antiepileptic drug monotherapy comparison studies 
 
Reference Antiepileptic  
drugs compared 
Study Population Conclusions Comments 
 Marson et al, 
2000 
Carbamazepine 
Sodium valproate 
Children and adults with 
partial-onset seizures, or 
generalised-onset tonic-clonic 
seizures 
Some evidence supported use of carbamazepine for 
partial-onset seizures. No evidence to support use of 
valproate in generalised-onset seizures. 
Misclassification of 
epilepsy may have 
confounded results. 
Tudur Smith 
et al, 2001 
Phenytoin 
Sodium valproate 
Children and adults with 
partial-onset or primary 
generalised tonic-clonic 
seizures 
No significant differences in efficacy outcomes 
between the two drugs. 
 
 Tudur Smith 
et al, 2003 
Carbamazepine 
Phenobarbital 
Adults and children with 
partial-onset or primary 
generalised tonic-clonic 
seizures 
Drugs were equally effective at controlling focal-onset 
and primary generalised tonic-clonic seizures. 
 
 Taylor et al, 
2003 
Phenobarbital 
Phenytoin 
Adults and children with 
partial-onset or primary 
generalised tonic-clonic 
seizures 
Phenobarbital was significantly more likely to be 
discontinued than phenytoin. 
No difference in time to 12-month remission or first 
seizure. 
Differences in study 
design made 
comparisons difficult. 
 Posner et al, 
2005 
Ethosuximide 
Sodium valproate 
Lamotrigine 
Children and adolescents with 
absence seizures 
Evidence was insufficient to make conclusions 
regarding efficacy 
Trials included were of 
poor methodological 
quality with small 
patient numbers. 
Muller et al, 
2006 
Phenytoin 
Oxcarbazepine 
 
 
Children and adults with 
epilepsy 
For patients with partial-onset seizures, oxcarbazepine 
is significantly less likely to be withdrawn. Data did 
not allow efficacy comparisons. 
Misclassification of 
epilepsy types may 
have confounded 
results. 
Gamble et al, 
2006 
Carbamazepine 
Lamotrigine 
Children and adults with 
partial-onset seizures or 
generalised seizures with or 
without other seizure types 
Carbamazepine may be superior to lamotrigine in 
terms of seizure control for time to first seizure. 
Studies of a longer 
duration are required to 
assess long-term 
outcomes. 
5.4 Safety 
Establishing acceptable tolerability is a crucial function of regulatory studies 
performed by pharmaceutical companies for licensing purposes.  On occasion, a 
safety issue will occur once a drug becomes available for general clinical use. This 
was the case with felbamate, which was found to cause hepatic failure and aplastic 
anaemia, severely limiting its use (Kaufman et al, 1997), and with vigabatrin, where 
peripheral visual field defects were first documented eight years after the drug was 
licensed (Krauss et al, 1998). Other AEDs, such as carbamazepine (Pellock, 1987), 
phenytoin (Haruda, 1979), lamotrigine (Brodie et al, 1995), oxcarbazepine (Bill et al, 
1997), and zonisamide (Arif et al, 2007) have been associated with idiosyncratic 
hypersensitivity reactions. Recent data support a particular association between the 
HLA-B*1502 allele and AED-induced cutaneous reactions in Han Chinese (Man et 
al, 2007). Such idiosyncratic reactions are the result of an abnormal interaction 
between the drug and the patient, usually through cytotoxic or immunologic effects 
triggered by the drug or its metabolites (Ju and Uetrecht, 2002). These can be 
minimised by a low starting dose and slow titration schedule.  
 
5.5 Teratogenicity 
The incidence of minor and major foetal malformations increases in women with 
epilepsy, even if they are untreated (Holmes et al, 2001). Commonly quoted figures 
are 3 - 6% for women with epilepsy compared with 2 - 3% in the general population 
(Tomson et al, 2004).  The risk increases disproportionately with the number of AEDs 
taken, being approximately 3% for one drug (similar to background risk), 5% for two, 
10% for three and over 20% in women taking more than three AEDs.  A syndrome  
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ascribed initially to hydantoins including phenytoin (foetal hydantoin syndrome), but 
now known to occur with other AEDs including carbamazepine and valproate, 
consists of facial dimorphism, cleft lip and palate, cardiac defects, digital hypoplasia  
and nail dysplasia (Tomson et al, 2004).  
 
Current evidence suggests that the risk of major congenital malformations is 2-4 times 
higher with the use of valproic acid compared to other AEDs such as carbamazepine 
and lamotrigine, although this may be minimised by keeping the daily dose at or 
below 1000 mg (Harden et al, 2009).  Absolute rates have ranged from 6 – 11%. 
Exposure to high dose valproic acid in utero may impair later cognitive function 
(Meador et al, 2009).  The risk of major malformations with high dosage lamotrigine 
requires resolving (Morrow et al, 2006).    
 
 
 
5.6 Tolerability 
For an AED to be effective, it requires to be well-tolerated, as well as having efficacy. 
AEDs can produce unwanted dose-related side effects, with central nervous system 
(CNS) effects such as drowsiness, ataxia and dizziness being the most common. As 
with idiosyncratic reactions, these can be minimised by a low starting dose and slow 
titration schedule. Several of the newer agents have been shown to have superior 
tolerability (Dam et al, 1989; Brodie et al, 1995; Kalviainen et al, 1995; Reunanen  
et al, 1996; Bill et al, 1997), although seizure freedom may still be unattainable due to 
the development adverse effects in some patients. Specific adverse effects associated 
with AED treatment are discussed in detail in Chapter 9. 
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5.7 Pharmacokinetic properties 
Ideally, an AED should be absorbed fully, have low protein binding and undergo 
linear pharamacokinetics, with clearance unaffected by renal impairment (Perucca, 
2005). It should neither induce nor inhibit hepatic mono-oxygenase or conjugating 
enzymes, interact with concomitant medication, nor produce neurotoxic or other 
adverse effects. A long elimination half-life is advantageous, allowing once or twice 
daily dosing. A well-established target dose should be achievable without titration. 
Many older AEDs, to some extent, undergo hepatic metabolism, with renal 
elimination of inactive metabolites (Table 8, page 49). Phenytoin pharmacokinetics 
are complex. With increasing doses, the eliminating enzyme system becomes 
progressively saturated. Thus, a small increase in dose can result in a large rise in 
plasma concentration and neurotoxicity (Valodia et al, 2000).  
 
Phenobarbital, primidone, phenytoin, and carbamazepine induce the metabolism of 
lipid-soluble drugs such as the combined oral contraceptive pill (COCP) (Back et al, 
1980), cytotoxic agents (Kivisto et al, 1995), antiretrovirals (Liedtke et al, 2004), 
statins (Ucar et al, 2004), and warfarin (Solomon et al, 1972). Newer AEDs are less 
likely to interfere with hepatic metabolism (Table 9, page 50), although oxcarbazepine 
(Klosterskov Jensen et al, 1992, Fattore et al, 1999), felbamate (Saano et al, 1995), 
and higher doses of topiramate (Rosenfeld et al, 1997a) can induce the oestrogenic 
component of the COCP (Patsalos et al, 2008). Lamotrigine reduces levonorgestrel 
concentrations, but has no effect on ethinyloestradiol concentrations (Sidhu et al, 
2005). Conversely, lamotrigine clearance is increased two-fold by the co-
administration of the COCP (Sabers et al, 2001; Sabers et al, 2003; Reimers et al, 
2005; Christiensen et al, 2007; Wegner et al, 2009), a likely consequence of the 
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induction of the uridine diphosphate glucuronosyltransferase system, via which 
lamotrigine is metabolised (Cohen et al, 1987). 
 
Where there is a linear relationship between dose and plasma concentration, 
concentration monitoring can be helpful in assessing side effects, compliance, and in 
establishing the most effective concentration in a seizure-free patient (Patsalos et al, 
2008). Routine measurement of plasma concentrations of newer AEDs is not 
recommended, as they do not correlate well on a population basis with efficacy or side 
effects. Therapeutic drug monitoring can play a useful role in individualising clinical 
management, provided that drug concentrations are measured at an appropriate time 
in an appropriate patient with a clear indication, and are interpreted correctly.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Pharmacokinetic interactions of established antiepileptic drugs (AEDs) 
References AED Undergoes hepatic 
metabolism 
Affects hepatic 
cytochrome P450  
enzymes 
Affects metabolism 
of other AEDs 
Metabolism affected 
by other AEDs 
Hansen et al, 1971; 
Christiansen and Dam, 1973;  
Brodie et al, 1983;  
Kerr et al, 1994 
Carbamazepine Yes Yes Yes Yes 
Jawad et al, 1984;  
Sennoune et al, 1992 
Clobazam Yes No No Yes 
Lai et al, 1978;  
Khoo et al, 1980 
Clonazepam Yes No No Yes 
Warren et al, 1980;  
Giaccone et al, 1996 
Ethosuximide Yes No No  Yes 
Christiansen and Dam, 1973; 
Callaghan et al, 1977; Eadie et 
al, 1977; Bruni et al, 1980 
Phenobarbital Yes Yes Yes Yes 
Christiansen and Dam, 1973; 
Khoo et al, 1980; Duncan et al, 
1991; Bajpai et al, 1996 
Phenytoin Yes Yes Yes Yes 
Alvin et al, 1975; Porro et al, 
1982; Brodie et al, 1983; Sato 
et al, 1992 
Primidone Yes Yes Yes Yes 
Bowdle et al, 1979;  
Bruni et al, 1980;  
Pisani et al, 1984;  
Sadeque et al, 1997 
Valproate Yes Yes Yes Yes 
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Table 9. Pharmacokinetic interactions of modern antiepileptic drugs (AEDs) 
References AED Undergoes hepatic 
metabolism 
Affects hepatic cytochrome P450  
enzymes 
Affects metabolism of 
other AEDs 
Metabolism affected by 
other AEDs 
Fuerst et al, 1988;  
Graves et al, 1989; 
Wagner et al, 1994 
Felbamate Yes Yes Yes Yes 
Volmer et al, 1986 ;  
Hooper et al, 1991; 
Radulovic et al, 1994 
Gabapentin No No No No 
Ben-Menachem et al, 2007 
 
Lacosamide Yes No No No 
Cohen et al, 1987;  
Brodie et al, 1997;  
Besag et al, 1998 
Lamotrigine Yes No No Yes 
Nicolas et al, 1999;  
Gidal, et al, 2005 
Levetiracetam No No No Yes*  
Wagner and Schmidt, 1987; 
Larkin et al, 1991;  
McKee et al, 1994 
Oxcarbazepine Yes Yes Yes*  Yes 
Brodie et al, 2005 Pregabalin No No No No 
Lau et al, 1997;   
Gustavson et al, 1998a, 
Gustavson et al, 1998b 
Tiagabine Yes No No Yes 
Sachdeo et al, 1996 ; 
Rosenfeld et al, 1997b 
Topiramate Yes Yes Yes*  Yes 
Haegele and Schechter, 
1986;  
Rimmer and Richens, 1989 
Vigabatrin No No Yes* No 
Ojemann et al, 1986;  
Nakasa et al, 1993 
Zonisamide Yes No  No Yes 
* effect modest 
5.8 Formulation 
Readily identifiable and palatable formulations can help to improve adherence, and 
thus seizure control. As well as being manufactured as tablets, several AEDs are 
available in alternative formulations such as syrup and sprinkles which can be useful 
in patients with swallowing difficulties, and for those with percutaneous endoscopic 
gastrostomy tubes. Parenteral formulations are invaluable in the rapid treatment of 
status epilepticus, and in other emergency circumstances where oral access is not 
available. The use of rectal diazepam to abolish prolonged seizure activity is now 
being superseded by the administration of buccal, or nasal midazolam (Scott et al, 
1999; Wilson et al, 2004). Intravenous formulations are available for sodium 
valproate, levetiracetam, and lacosamide, in addition to phenytoin, fosphenytoin, 
phenobarbital, and the benzodiazepines, clonazepam, diazepam, lorazepam, and 
midazolam. 
 
 
5.9  Cost 
Despite the introduction of several novel agents, price remains an important factor in 
determining the global use of antiepileptic medication. With few differences in 
efficacy amongst AEDs, the low costs of older drugs such as phenobarbital and 
phenytoin make these agents an attractive option for third world countries. One 
thousand generic 100-mg phenobarbital tablets currently cost $6.16 (International 
Drug Price Indicator Guide, 2009). This is considerably less than treatment with any 
of the new AEDs. 
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6.   Antiepileptic drug treatment of common epilepsy syndromes  
6.1 Idiopathic generalised epilepsy syndromes with onset in adulthood 
As is discussed in Chapter 3, the term ‘idiopathic’ is now used for well-characterised 
forms of epilepsy, mainly occurring in childhood and adolescence, and believed (but 
not necessarily proven) to have a genetic basis. Inheritance is likely to be complex, 
and underlying genetic causes are slowly being unravelled. It has been shown recently 
that 1% of people with idiopathic generalised epilepsies have a recurrent 
microdeletion on chromosome 15q13.3, leading to the deletion of seven genes (Helbig 
et al, 2009). In young adults, there are three idiopathic generalised epilepsy 
syndromes which can present at this time of life – JME, juvenile absence epilepsy, 
and epilepsy with generalised tonic-clonic seizures on awakening. 
 
6.1a  Juvenile myoclonic epilepsy 
JME, the commonest syndrome in this population, accounts for 3% to 12% of all 
epilepsies. Often life-long, the syndrome consists of tonic-clonic seizures, myoclonic, 
and absence seizures (Specchio and Beghi, 2004). Onset is generally in the second 
decade, but can be earlier, or later. Patients may initially present with tonic-clonic 
seizures, but on close questioning, it may transpire that myoclonic jerks occur with 
fatigue or sleep deprivation. A history of absence seizures can be elicited by direct 
inquiry about ‘blank spells’. These are often mild and simple, compared to those in 
absence epilepsies. Photosensitivity can occur in up to one third of patients with JME 
(Wolf and Goosses, 1986). During myoclonic jerks, the EEG may show spike-and-
wave discharges which are often irregular, or polyspike-waves. These can occur 
between the jerks.  Neuroimaging studies have shown abnormalities in mesial frontal 
structures in many, and more widespread cortical grey matter abnormalities in others 
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(Woermann et al, 1999). Like most idiopathic generalised epilepsies, it is likely that 
JME is often inherited as a multifactorial or complex trait, with the additive effects of 
several or many susceptibility genes, and interaction with environmental factors 
producing the final phenotype. Autosomal dominant inheritance was found in one 
family (Cossette et al, 2002). The GABRA1 gene, which encodes the α1 subunit of 
the GABAA receptor, was postulated as a major effect gene. This was not the case in 
other series (Shaochun et al, 2006). Autosomal recessive inheritance has been 
suggested in some patients (Panayiotopoulos and Obeid, 1989). Susceptibility genes 
such as CLCN2 (Haug et al, 2003) and EFHC1 (Suzuki et al, 2004) have also been 
identified.  
 
 
6.1b  Juvenile absence epilepsy 
Juvenile absence epilepsy usually manifests between the ages of 7 and 17, with a peak 
at 10 to 12 years (Janz, 1997). Absence seizures generally occur less often, and may 
be less severe than in childhood absence epilepsy. Automatisms are frequent. Random 
and infrequent myoclonic jerks, as well as infrequent generalised tonic-clonic seizures 
occur in most patients (Wolf and Inoue, 1984; Panayiotopolous et al, 1989). One fifth 
of patients also suffer attacks of absence status epilepticus (Agathonikou et al, 1998). 
As with childhood absence epilepsy, photosensitivity can be present, but in juvenile 
absence epilepsy this is significantly more likely to occur in female patients (Janz, 
1997). Juvenile absence epilepsy is usually a life-long disorder, but absences tend to 
become less severe with age. A family history of epilepsy is common with 31% of 
relatives having childhood absence epilepsy and 2.5% having JME (Marini et al, 
2004).  The interictal and ictal EEG characteristically shows generalised symmetric 
 53
spike-and-wave discharges, generally faster than 3Hz (3.5 to 4Hz) with frontal 
accentuation (Panayiotopoulos et al, 1989). Functional MRI-EEG studies have shown 
activation predominating over deactivation in the thalamus, and the opposite in the 
cerebral cortex (Aghakhani et al, 2004).  
 
6.1c Epilepsy with tonic-clonic seizures on awakening 
Epilepsy with tonic-clonic seizures on awakening generally manifests during teenage 
years (ILAE Commission on Classification and Terminology, 1989). There is a male 
predominance. The vast majority of the tonic-clonic seizures occur shortly after 
awakening, regardless of time of day. There may be seizures in the evening during 
relaxation, or following sleep deprivation. Absence and myoclonic seizures can be 
associated with the condition, and there is a positive correlation with photosensitivity 
(Wolf and Goosses, 1986). The interictal EEG is abnormal in the majority, with spike-
and-wave activity, slow waves, and disorganised background activity (Janz, 2000). 
 
AEDs effective against idiopathic generalised epilepsies include valproic acid 
(Marson et al, 2007a), topiramate (Biton et al, 1999), levetiracetam (Abou-Khalil et 
al, 2003; Cohen, 2003; Kasteleijn-Nolst Trenité and Hirsch, 2003; Krauss et al, 2003; 
Lagae et al, 2003, Brodie et al, 2007), zonisamide (Yagi and Seino, 1992; Kyllerman 
and Ben-Menachem, 1998; Newmark and Dubinsky, 2004; Kothare et al, 2004; 
Wilfong and Schultz, 2005; Marinas et al, 2009), phenobarbital (Placencia et al, 
1993), and clobazam (Keene et al, 1990) (Table 4, page 38). Lamotrigine also has 
efficacy, but may make myoclonic jerks worse (Guerrini et al, 1998; Guerrini et al, 
1999; Carrazana et al, 2001). Ethosuximide (Posner et al, 2005) and lamotrigine 
(Holmes et al, 2008) are useful in controlling absence seizures.  
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6.2 Localisation-related epilepsies 
People with localisation-related seizures have been reported to have a poorer outcome 
than those with idiopathic generalised epilepsies (Annegers et al, 1979; Devinsky, 
1999; Kwan and Brodie, 2000a). The British National General Practice Study of 
Epilepsy reported 69% of people with idiopathic generalised epilepsies as having five 
years’ seizure freedom at nine year follow-up, compared to 61% for those with remote 
symptomatic epilepsy (Cockerell et al, 1997). In recent years, the detection of subtle 
structural lesions in patients with localisation-related epilepsy has improved with the 
widespread use of high resolution MRI. Together with the influx of AEDs onto the 
marketplace, this has increased the scope for managing this patient population, with 
the possibility of improving prognosis. 
 
Given these advances in management, it was decided, therefore, to investigate the 
response to AED treatment in an audit of 550 patients with localisation-related 
epilepsy, followed up at the Epilepsy Unit over 13 years (Stephen et al, 2001a - Paper 
i). Of these, 312 (57%) became seizure-free for a minimum of one year. Mesial 
temporal sclerosis was associated with the poorest outcome (n=73, 42% seizure-free, 
p<0.01), and a higher incidence of febrile convulsions (p<0.001) compared with 
arteriovenous malformation (n=14, 78% seizure-free), cerebral infarction (n=46, 67% 
seizure-free), primary tumour (n=35, 63% seizure-free), cortical gliosis (n=81, 57% 
seizure-free), cerebral atrophy (n=49, 55% seizure-free) and cortical dysplasia (n=63, 
54% seizure-free). Patients with symptomatic, and with cryptogenic epilepsies had 
similar outcomes. A family history of epilepsy was more likely in people with mesial 
temporal sclerosis, cortical dysplasia, and cryptogenic epilepsy than other groups 
(p=0.02). It is acknowledged, however, that the cross-sectional nature of this study 
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and the fact that patients newly started on treatment, and those with refractory 
epilepsy were included, will have introduced bias, and thus any statistical conclusions 
drawn may not be robust. 
 
6.2a  Hereditary aspects of focal-onset seizures 
One of the outcomes from the audit was that a family history of epilepsy was more 
likely with cortical dysplasia, cryptogenic epilepsy, and mesial temporal sclerosis than 
with other causes. There may be a number of reasons for this finding. In patients with 
abnormalities of cortical development genetic mutations are increasingly being 
identified. Underlying mechanisms include abnormal functioning proteins which can 
result in failure of initiation of neuronal migration, failure of ongoing migration, and 
failure in cortical lamination. These can lead to the spectrum of 
lissencephaly/pachygyria/subcortical band heterotopia, periventricular nodular 
heterotopia, and polymicrogyria.  
 
Lissencephaly can be the result of failure of ongoing migration. In classical (type I) 
lissencephaly the brain surface is completely, or almost completely, devoid of gyri 
and sulci. The spectrum ranges from agyria and pachygyria to subcortical band 
heterotopia with a relatively normal gyral pattern (Palmini et al, 2004). Affected 
patients have been found to have defects in the LIS1 gene on chromosome 17p13.3 
(Pilz et al, 1998). This is thought to lead to defects in cell migration, division, and 
morphogenesis, via disruption in the regulation of the microtubule motor protein 
cytoplasmic dynein, and problems with platelet-activating factor acetylhydrolase 
(Smith et al, 2000). LIS1 abnormalities are found in the Miller-Dieker syndrome and 
isolated lissencephaly sequence. Patients with Miller-Dieker syndrome have 
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lissencephaly at the severe end of the spectrum, distinct facial features, and other 
associated congenital abnormalities (Dobyns et al, 1991). Those with isolated 
lissencephaly sequence have small deletions or intragenic mutations of LIS1 (Pilz et 
al, 1998). X-linked lissencephaly can result from defects in the DCX (XLIS) gene. 
This affects doublecortin production, producing lissencephaly and subcortical band 
heterotopia (Haverfield et al, 2009). Abnormalities in the RELN gene can result in 
defects in reelin, an extracellular matrix-associated protein important in the regulation 
of neuronal migration during cerebral cortical development (Hong et al, 2000). This 
can produce lissencephely and cerebellar hypoplasia (Kerner et al, 1999; Ross et al, 
2001). Cobblestone (Type II) lissencephaly occurs in a group of disorders such as the 
Walker-Warburg syndrome, muscle-eye-brain disease and Fukuyama congenital 
muscular dystrophy. Inheritance is thought to be autosomal recessive in many of these 
conditions (Fukuyama et al, 1981; Dobyns et al, 1989; Santavuori et al, 1989).  
 
Failure of neuronal migration to the cortical plate can result in periventricular nodular 
heterotopia (Fox et al, 1998). Based on imaging and clinical data, five classification 
groups have been proposed: bilateral and symmetrical, bilateral single-noduled, 
bilateral and asymmetrical, unilateral, and unilateral with extension to neocortex 
(Battaglia et al, 2006). Bilateral periventricular nodular heterotopia is the most 
common type and mutations in FLNA, encoding the protein filamin A, are responsible 
for the X linked dominant form (Sole et al, 2009). Linkage to the Xq28 chromosome, 
with defects in the FLN1 gene and filamin 1 abnormalities occur in many familial 
cases (Kamuro and Tenokuchi, 1993; Bielas et al, 2004). The condition can be 
associated with pregnancy loss and male lethality (Eksioglu et al, 1996). 
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The polymicrogyria spectrum can vary in severity from unilateral focal disease to 
bilateral generalised disease. Neurological problems tend to be associated with the 
more severe forms. Polymicrogyria most often occurs as an isolated feature, although 
it can occur with other brain abnormalities. It is a feature of several genetic syndromes 
characterized by intellectual disability and multiple birth defects. These include 22q11 
deletion syndrome (Bassett et al, 2005), Adams-Oliver syndrome (Temtamy et al, 
2007), Aicardi syndrome (Saito et al, 2009), Galloway-Mowat syndrome 
(Kucharczuk et al, 2000), Joubert syndrome (Parisi, 2009), and Zellweger syndrome 
(Krause et al, 2009). Some families with a history of polymicrogyria have PAX6 gene 
mutations; others with bilateral frontal polymicrogyria and bilateral generalised 
polymicrogyria have autosomal recessive disorders (Chang et al, 2004). Patients with 
autosomal recessive bilateral generalised polymicrogyria have symmetrical 
polymicrogyria most prominent in the fronto-parietal cortex, leading to seizures, 
cognitive and motor delay. Sporadic cases of bilateral frontal polymicrogyria are also 
recognised, where the polymicrogyria is found from the frontal poles to the pre-
central gyrus, resulting in cognitive and motor delay, seizures, and spastic 
quadriparesis (Guerrini et al, 2000). Bilateral parasagittal parieto-occipital 
polymicrogyria occurs in sporadic fashion (Guerrini et al, 1997). These patients have 
bilateral polymicrogyria in the parasagittal areas and in the medial aspects of the 
occipital cortex, resulting in partial seizures and mental impairment.  
 
Failure in cortical lamination is generally sporadic, resulting in focal cortical 
dysplasias and microdysgenesis. These are discussed in detail later in this chapter. 
EMX2 gene defects have been linked to a few familial cases of schizencephaly 
(Tietjen et al, 2007).  
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With an increasing number of genetic defects being found in patients with these 
cerebral anomalies, some patients with cortical dysplasias in the audit may have had 
such diagnoses, thus explaining the high likelihood of a positive family history for 
epilepsy or seizures. Unfortunately, the original dataset no longer exists to examine 
this hypothesis. 
 
It is perhaps conceivable, that although 63 patients were classified as having focal 
cortical dysplasias, tuberous sclerosis could have been the underlying pathology in a 
small number. This again could account for a positive family history in some patients. 
Tuberous sclerosis, an autosomal dominant disorder, results from mutations in one of 
two non-homologous protein encoding genes, TSC1 and TSC2 (Niida et al, 1999). 
The TSC1 gene encodes hamartin, which may contribute to cell adhesion and 
migration. The TSC2 gene encodes tuberin, involved in regulation of DNA synthesis 
and the cell cycle. This results in the development of multiple hamartomas involving 
many organs. The major features of CNS tuberous sclerosis are giant cell 
astrocytomas, subependymal nodules, and cortical tubers, all of which can result in 
seizures. Cortical tubers are histologically characterised by the presence of dysplastic 
neurones and abnormal balloon cell glia, and have histological similarities to focal 
dysplasia lesions. It has been suggested that focal cortical dysplasias may represent a 
‘forme fruste’ of tuberous sclerosis (Taylor et al, 1971). Usually the distinction 
between the two can be made, taking into account clinical, radiological and genetic 
information. Recent genetic and pathological research suggests that the two are of 
independent aetiology (Baybis et al, 2004; Chandra et al, 2007). 
 
 59
It may be that some of the patients classified as having cryptogenic epilepsy and 
having normal brain MRIs, had cortical malformations which were not detected with 
this investigation. Such lesions include focal cortical dysplasias Type I and II as 
defined by Palmini and colleagues (Palmini et al, 2004), and mild malformations of 
cortical development generally referred to as microdysgenesis.  Such lesions are too 
subtle to be detected with MRI, with diagnosis requiring histological confirmation.  
These dysplasias are presumed developmental abnormalities of the cortical plate 
cytoarchitecture, usually with preservation of the gyral pattern. They can be graded 
histologically into type I (no dysmorphic neurons or balloon cells) and type II 
(dysmorphic neurons with or without balloon cells), with further subgrading 
according to the presence or not of architectural abnormalities.  
 
The term microdysgenesis, covers a wide spectrum of microscopic tissue findings, 
probably the result of cortical maldevelopment. The name itself, together with 
diagnostic criteria and diverse terminology, are the subject of much debate. These 
lesions have also been found in patients who do not have epilepsy (Kaufman et al, 
1989; Humphreys et al, 1990). As well as being the primary underlying cause of 
seizure activity, microdysgenesis may be a ‘dysplastic susceptibility factor’ 
contributing to the pathogenesis of hippocampal sclerosis (Blumke et al, 2002; Kasper 
et al, 2003). It may therefore be a predisposing factor to the development of 
hippocampal sclerosis after an insult such as a febrile convulsion. Evidence to suggest 
that some microdysgenesis lesions have a genetic component include the fact that 
when relatives of affected patients underwent quantitative MRI, a greater number of 
structural abnormalities were revealed than would be expected (Merschhemke et al, 
2003). Original reports of microdysgenesis were derived from patients with primary 
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generalised epilepsy (Meencke and Janz, 1984; Meencke and Janz, 1985), which may 
have a genetic basis in some (Panayiotopoulos and Obeid, 1989; Cossette et al, 2002; 
Haug et al, 2003; Suzuki et al, 2004; Shaochun et al, 2006).  
 
It was found in the audit that patients with mesial temporal sclerosis were more likely 
to have a family history of epilepsy or seizures. Familial temporal lobe epilepsy is a 
recognised clinical syndrome (Berkovic et al, 1996). In one subgroup, patients 
generally had a good prognosis, with frequent simple partial seizures, but infrequent 
complex partial seizures and rare secondary generalisation (Berkovic et al, 1996). Of 
22 affected families fulfilling the diagnostic criteria for familial temporal lobe 
epilepsy, MRI findings were variable, with 57% of 68 patients having hippocampal 
atrophy (Kobayashi et al, 2001). Seizure control also varied widely, but tended to be 
poorer in those with more severe hippocampal atrophy (Kobayashi et al, 2003). A 
genetic locus for this group has been identified on chromosome 4q (Hedera et al, 
2007). Another series of affected relatives in whom clinical presentation was more 
heterogeneous, and outcome not so positive, was studied (Cendes et al, 1998). 
Pedigree analysis suggested autosomal dominant inheritance with incomplete 
penetrance. Genetic loci for temporal lobe epilepsy preceded by febrile seizures have 
been identified on chromosome 12q22-q23, and a bilineal inheritance on 18q and 
1q25-q31 (Baulac et al, 2001; Claes et al, 2004). Mutations of the leucine-rich, 
glioma-inactivated 1 (LGI1) gene have been identified as a cause of a lateral temporal 
lobe epilepsy with frequent auditory auras (Kalachikov et al, 2002; Morante-Redolat 
et al, 2002; Ottman et al, 2004; Hedera et al, 2004). 
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6.2b  Repeat analysis in a cohort of newly diagnosed patients 
Because of the nature of the audit, these measures were repeated, therefore, in a cross-
sectional study 558 subjects with newly diagnosed localisation-related epilepsy, 
followed up over a period of 20 years (Mohanraj and Brodie, 2005a). Although this 
audit was again limited by its observational nature, compared with the previous 
project (Stephen et al, 2001a - Paper i), a higher percentage of patients with 
hippocampal atrophy (50% versus 42%) and cortical dysplasia (60% versus 54%) 
became seizure-free. Overall, 343 (62%) subjects became controlled on AED 
treatment. These results show that localisation-related epilepsies are not necessarily 
associated with poor outcomes. Others have corroborated this finding ((Andrade-
Valenca et al, 2003). Improved seizure freedom rates in this second analysis may 
reflect the fact that this cohort contained newly diagnosed patients only, around 60% 
of whom will control on their first or second monotherapy (Kwan and Brodie, 2000a).   
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7. Antiepileptic drug treatment of refractory epilepsy 
7.1 Defining ‘refractory epilepsy’ 
Although many new AEDs have been introduced in recent years, around one third or 
people with epilepsy will never achieve remission (Annegers et al, 1979; Cockerell et 
al, 1995; Mattson et al, 1996; Kwan and Brodie, 2000a; Mohanraj and Brodie, 
2005b). Medically refractory epilepsy is increasingly accepted as a distinct multi-
faceted entity. The definition of the condition and the understanding of underlying 
mechanisms is the cause of much debate. This is reflected in the fact that two different 
definitions of refractory epilepsy were employed in the studies of adjunctive 
topiramate (Paper iii) and levetiracetam (Paper v) contained in this thesis.  
 
The subject of drug resistant epilepsy is being examined currently by a Task Force of 
the ILAE Commission on Therapeutic Strategies (Commission on Therapeutic 
Strategies Task Force, ILAE, in press). The Task Force has developed a core 
definition which states that ‘drug refractory epilepsy may be defined as failure of 
adequate and appropriate trials of two well tolerated and appropriately chosen and 
used antiepileptic drugs (whether as monotherapies or in combination) to achieve 
seizure freedom for either one year or three times the pre-intervention inter-seizure 
interval, whichever is the longer.’ Refractory epilepsy is multi-dimensional, with 
failure to respond to AED treatment being associated with neurobiochemical plastic 
changes, cognitive decline, and psychosocial dysfunction (Kwan and Brodie, 2002). 
These, in turn, can lead to dependent behaviour and a restricted lifestyle. 
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7.2  Mechanisms of resistance 
Studies suggest there are at least four categories of AED resistance – some patients 
have refractory seizures de novo, whereby remission is never achieved from the onset 
of epilepsy (Camfield et al, 1997; Kwan and Brodie, 2000b). Others have developed 
progressive refractoriness, where there is initial seizure freedom, but seizures then 
recur and become uncontrollable (Camfield et al, 1997; Berg et al, 2003; Mohanraj 
and Brodie, 2006). There may also be a wax-and-wane pattern where the epilepsy 
alternates between being controlled and uncontrolled (Mohanraj and Brodie, 2006). In 
around 12% of patients the epilepsy is drug-resistant initially, but with time and AED 
manipulation, becomes drug responsive (Kwan and Brodie, 2000a; Kwan and Brodie, 
2000b; Mohanraj and Brodie, 2006). Several hypotheses have been used to explain 
medically refractory epilepsy, including the target hypothesis and the multidrug-
transporter hypothesis. 
 
7.2a  Target hypothesis 
The target hypothesis postulates that an alteration in the cellular targets of AEDs leads 
to a reduction in their sensitivity to treatment (Remy et al, 2003). Evidence for this 
theory includes the loss of voltage-dependent sodium channels of dentate granule cells 
by carbamazepine in hippocampi resected from patients with carbamazepine-resistant 
temporal lobe epilepsy (Remy et al, 2003). Alterations in GABAA receptor subtype 
expression were found in a group of patients with drug-resistant temporal lobe 
epilepsy (Loup et al, 2000). However, the mechanism of action of many AEDs is not 
fully understood, and this theory does not explain why some patients have epilepsy 
resistant to AEDs with multiple mechanisms of action, or to different AEDs with 
different mechanisms of action.  
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7.2b  Transporter hypothesis 
The transporter hypothesis suggests there is over-expression of efflux drug 
transporters at the cerebral capillary endothelium which constitute the blood-brain 
barrier. Efflux transporters, which include P-glycoprotein and multidrug-resistance-
associated proteins, are transmembrane molecules situated in the apical membrane of 
capillary endothelial cells which form the blood brain barrier. These actively pump 
their substrates against the concentration gradient, thus reducing intracellular 
accumulation. Overexpression would therefore decrease the accumulation of substrate 
AEDs at the site of action, making their action ineffective. The actions of P-
glycoprotein have been studied widely (Tischler et al, 1995; Sisodiya et al, 2002). 
Pathologically elevated expression of P-glycoprotein has been found in the region of 
experimentally induced seizure foci, and in association with a number of clinical 
neuropathologies associated with uncontrolled seizures (Sisodiya et al, 2002).  
 
A number of AEDs have been mooted as substrates for P-glycoprotein, and/or 
multidrug-resistance-associated proteins, although there are few data to support this 
hypothesis. It is unclear, however, as to whether over-expression of drug transporter 
proteins is intrinsic or a consequence of uncontrolled seizures, AED treatment, or 
both. Initial evidence suggested that the 3435>T polymorphism of the ABCB1 (also 
called MDR1) gene which encodes P-glycoprotein may be associated with a poorer 
response to AED treatment in Caucasians (Siddiqui et al, 2003). Others think this may 
be an epiphenomenon (Tan et al, 2004; Sills et al, 2005). Problems arise as the 
majority of research has been performed in patients with pharmacoresistant epilepsy, 
the definition of which has varied in different studies. Specimens have been obtained 
from patients who have undergone epilepsy surgery, and there is a lack of suitable 
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controls. Experimental models have provided little evidence to back the human data, 
and are complicated by probable species differences in the P-glycoprotein transport of 
AEDs (Crowe and Teoh, 2006; Baltes et al, 2007a, Baltes et al, 2007b).  
 
7.2c  Other factors 
There may be other factors contributing towards the development of refractoriness. 
These include disease-related causes such as neuropathology, disease progression, 
structural brain changes, hypexcitable and disinhibited neuronal network 
reorganisation (for example - mossy fibre sprouting) (Tauck and Nadler, 1985; 
Okazaki et al, 1995).  Other mechanisms include alterations in neuroreceptors (for 
example - composition/functioning of GABA/glutamate receptors) (Kapur and 
Macdonald, 1997; Macdonald and Kapur, 1999; Jones et al, 2002), ion 
channelopathies (Singh et al, 1998; de Fusco et al, 2000; Wallace et al, 2001; Claes et 
al, 2003), reactive autoantibodies (McKnight et al, 2005), and impaired drug 
penetration (Potschka et al, 2002). Drug-related mechanisms include loss of efficacy 
(tolerance) and ineffective mechanism of action.  
 
 
 
7.3 Managing patients with refractory epilepsy 
Medically refractory epilepsy can pose a significant clinical challenge. Where seizures 
prove hard to control, it is worthwhile re-examining the diagnosis, as up to 30% of 
people with ongoing seizures have been found to have non-epileptic attacks (Smith et 
al, 1999). It is also important to ensure the patient is adherent with their medication. 
As discussed in Chapter 5, measurement of circulating AED concentrations can be 
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useful to this end. In those for whom the diagnosis of epilepsy is secure, ensuring 
optimisation of AED therapy appropriate for the seizure type or syndrome may 
improve seizure control.  
 
 
 
 
7.4 Pharmacological treatment 
Polytherapy has remained widely used in the treatment of epilepsy, although there is a 
lack of a robust evidence base and continued controversy over when and how it 
should be employed. Before the advent of the newer AEDs, it was commonplace to 
initiate treatment with polytherapy. This strategy changed following the observation 
that patients treated with two or more drugs had fewer side effects and improved 
seizure control when they were changed to monotherapy (Shorvon and Reynolds, 
1979; Schmidt, 1983). Conversion from polytherapy to monotherapy led to more 
adverse effects with only a modest increase in seizure frequency (Schmidt, 1982). 
However, these studies were performed in the days when AEDs consisted mainly of 
sodium channel blocking agents, the combining of which not infrequently leads to 
pharmacokinetic and pharmacodynamic interactions (Table 8, page 49; Table 9, page 
50). The licensing of newer AEDs, many of which have novel mechanisms of action, 
introduced the potential for combining drugs. 
The goal of combination treatment is to improve or completely control seizures with 
no or the fewest side effects and the least impact on quality-of-life. In general terms, 
several outcomes are possible – the combination may be of no benefit, or the drugs 
may work against each other; there can be equal benefit and/or side effects that are 
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less than or equal to the effect of each drug when given alone (additive); or there can 
be benefit and/or side effects that are greater than the effect of each drug when given 
alone (supra-additive). 
 
7.5  Drug Load 
It has been argued that the efficacy and toxicity of AED polytherapy is more related to 
total drug load than to number of drugs (Lammers et al, 1995; Deckers et al, 1997a). 
Drug load can be measured by the prescribed daily dose/defined daily dose ratio 
(Deckers et al, 1997b). The WHO defined daily dose indicates the assumed average 
maintenance dose per day used for its main indication in adults (WHO, 2009). 
Although this is a useful concept, it is currently difficult to apply in everyday clinical 
practice. 
 
7.6  Drug interactions 
When combining AEDs, it is important to take drug interactions into account. 
Pharmacokinetic interactions are the effects of drugs upon the disposition of one 
another, including changes in absorption, metabolism, protein binding, and excretion. 
These interactions may increase the risk of side effects and may impact on efficacy. 
The AEDs with the greatest potential for interaction are metabolised by the hepatic 
cytochrome P450 superfamily, and include phenobarbital, phenytoin, carbamazepine, 
primidone, and to some extent, topiramate and oxcarbazepine (Table 8, page 49). 
Valproic acid is a weak inhibitor of mono-oxygenase and conjugating enzymes, which 
can slow the clearance of other AEDs such as phenytoin and lamotrigine. In 
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comparison, fewer of the new AEDs interfere with the cytochrome enzyme system 
and are generally less likely to affect the metabolism of other AEDs to a clinically 
significant extent (Table 9, page 50). 
 
7.7  Mechanism of action 
With information increasingly becoming available on mechanism of action, it would 
seem sensible to combine drugs with different mechanisms, although it is becoming 
apparent that several AEDs act in multiple ways which are not yet understood fully. 
Three broad mechanisms of AED action are recognised: (i) modulation of voltage-
dependent ion channels, (ii) enhancement of inhibitory neurotransmission, and (iii) 
attenuation of excitatory neurotransmission (Table 10, page 70). It is now recognised, 
however, that all AEDs, with one or two exceptions, have multiple cellular effects. 
While it is convenient to categorise the mechanisms of actions of AEDs in this way, it 
is important to remember that understanding of the pathogenesis of seizure generation 
and propagation, and that of how drugs modulate these processes, remains 
rudimentary. The discovery that astrocytes may play a key role in seizure activity, and 
that in part, several AEDs may act to suppress astrocytic intracellular calcium ion 
signalling, challenges the traditional view (Tian et al, 2005).  
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Table 10. Perceived mechanisms of action of antiepileptic drugs  
 
(Adapted from Kwan and Brodie, 2007) 
 
Antiepileptic Drug ↓Na+ channels ↓Ca2+ channels** ↑GABA 
transmission 
↓ Glutamate 
transmission 
Established  
 
    
Benzodiazepines   ++  
Carbamazepine ++    
Ethosuximide  ++ (T-type)   
Phenobarbital  ? ++ ? 
Phenytoin ++    
Valproate ? ? (T-type) + ? 
Modern 
 
    
Felbamate + ? + + 
Gabapentin ? ++ (α2δ) +  
Lacosamide +a    
Lamotrigine ++ ?   
Levetiracetam*  ? ? ? 
Oxcarbazepine ++    
Pregabalin  ++ (α2δ)   
Rufinamide ++    
Stiripentol   ?+  
Tiagabine   ++  
Topiramate + + + + 
Vigabatrin   ++  
Zonisamide + + (T-type)   
 
GABA; Gamma aminobutyric acid 
*Levetiracetam acts by binding to synaptic vesicle protein 2A 
aLacosamide also binds to collapsin-response mediator protein 2 
**Unless otherwise stated, action on high voltage activated calcium channels 
++ Primary action; + Probable action; ? Possible action 
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7.8  When should combination therapy be used?  
7.8a  Initiation of treatment 
In the last 30 years, monotherapy has been generally recommended for patients 
starting treatment for newly diagnosed epilepsy. This is because evidence suggested 
combinations of older AEDs led to more side effects, with no improvement in 
efficacy (Shorvon and Reynolds, 1979; Schmidt, 1982; Schmidt, 1983). Using 
treatment calculated by drug load, this theory was challenged by a multicentre 
randomised double-blind study which found no difference in seizure frequency, 
neuro- or systemic toxicity between cohorts taking monotherapy or polytherapy 
(Deckers et al, 2001). A prospective observational project came to similar conclusions 
(Kwan and Brodie, 2000b). Never-the-less, with 60% of patients becoming seizure-
free with a modest dose of monotherapy (Kwan and Brodie, 2000a), and taking into 
account the enhanced teratogenic potential of polytherapy regimens (Harden et al, 
2009), it would seem appropriate to start with a single drug before opting for 
combination regimens.   
 
 
7.8b  After failure of one monotherapy regimen 
The management of the 30-40% of patients who do not become seizure-free on their 
first drug is widely debated. If the drug has to be discontinued because of side effects, 
the change to another drug is unavoidable. If however, persistence of seizures is the 
problem, clinical practice varies widely in whether to switch to another AED, or add a 
second drug (Baldy-Moulinier et al, 1998; Karceski et al, 2005). Switching resulted in 
seizure freedom in 13% of 470 newly diagnosed adults with a variety of seizure types 
in one prospective study (Kwan and Brodie, 2000a). Similar seizure-freedom and side 
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effect rates were found in patients who received substituted monotherapy (Kwan and 
Brodie, 2000b). A pragmatic randomised open-label multicentre study addressed this 
question in 157 patients with partial-onset seizures (Beghi et al, 2003). There was no 
significant difference in AED retention rate or probability of seizure freedom at 12 
months. There was a non-significant trend towards a lower percentage of patients 
experiencing or withdrawing as a result of adverse effects in the add-on group 
compared with the substitution group, but the study was under-powered.  
 
7.8c  After failure of more than one monotherapy regimen 
There have been no controlled studies looking at the number of single AED regimens 
that should be trialled and failed before commencing combination therapy. In one 
prospective project of 470 adult patients newly diagnosed with epilepsy, 47% became 
seizure-free with their first drug, 13% with their second AED, but only 1% with their 
third drug (Kwan and Brodie, 2000a). Similar results were obtained from an updated 
analysis five years later (Mohanraj and Brodie, 2006). These results suggest that if 
treatment with two appropriately chosen monotherapy regimens fails, the chances of 
complete seizure control with a third agent are slim.  
 
7.9  Studies of antiepileptic drug combination therapy 
Although many people with uncontrolled epilepsy take two or more AEDs, 
polytherapy regimens are rarely scrutinised in the clinical setting. Experimental 
models have suggested synergism when combinations of valproate with phenytoin 
(Chez et al, 1994) or ethosuximide (Bourgeois, 1988), topiramate with carbamazepine 
or phenobarbital (Shank et al, 1994), topiramate with lamotrigine or levetiracetam 
(Sills et al, 2004), or felbamate with carbamazepine, phenytoin, phenobarbital or 
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valproate are employed (Gordon et al, 1993). These have proved difficult to replicate 
in large scale clinical studies, and systematic reviews of phase III add-on trials have 
generally failed to identify major differences in efficacy or tolerability in the newer 
AEDs for the treatment of refractory localisation-related epilepsies (Marson et al, 
1997; Cramer et al, 1999; Marson et al, 2001). 
 
One randomised double-blind trial compared gabapentin with vigabatrin as first-add-
on drug for partial seizures which were not controlled with initial monotherapy 
(Lindberger et al, 2000). This study had to be terminated at 8 weeks, however, 
because of emerging concerns about vigabatrin-related visual field defects. There was 
no significant difference in the improvement rate, proportion of seizure-free patients, 
or quality-of-life scores.  
 
During a trial in 347 patients designed to assess the efficacy of lamotrigine, patients 
were administered lamotrigine with sodium valproate, carbamazepine, or phenytoin 
(Brodie et al, 1997). Superior efficacy was shown for the valproate/lamotrigine 
combination with 83% becoming seizure-free, compared to 43% taking 
carbamazepine/lamotrigine and 34% taking phenytoin/lamotrigine. Given the 
magnitude of the valproate/lamotrigine response, it was thought to be the result of a 
pharmacodynamic as well as a pharmacokinetic interaction between the two drugs 
(Pisani et al, 1999). Five patients with absence seizures refractory to either sodium 
valproate or ethosuximide became seizure-free with a combination of the two drugs 
(Rowan et al, 1983). High dose lamotrigine and topiramate led to complete seizure 
control in two patients previously refractory to either monotherapy (Stephen et al, 
1998). 
 73
7.10  Practical considerations 
When choosing an AED for a combination regimen, it is important to add in an agent 
appropriate for the seizure type or syndrome. The adverse event and interaction 
profile should have the potential to produce seizure freedom without intolerable 
adverse effects. Other factors such as age, sex, weight, psychiatric history, co-
medication and co-morbidity can all have a bearing on the selection process (Stefan et 
al, 2006). If the patient becomes seizure-free, or develops side effects, the dose of the 
initial monotherapy can be reduced, or the drug withdrawn in some instances. Many 
controlled patients, however, prefer to remain on polytherapy if they have struggled to 
gain seizure freedom with a single agent. Around 1% who fail to control on two drugs 
may become seizure-free with triple therapy, but control is unlikely to be achieved 
with four or more AEDs, and the risk of adverse effects increases with the heavier 
drug burden (Kwan and Brodie, 2000a). For patients deemed to have epilepsy 
refractory to AED treatment, those with surgically remediable causes may be suitable 
for epilepsy surgery (Wiebe et al, 2001), or other non-pharmacological options. 
 
 
7.11  Non-pharmacological options 
7.11a  Epilepsy surgery 
Some patients with medically resistant epilepsy, in particular those with discrete 
resectable lesions, can benefit from epilepsy surgery. In a randomised controlled trial, 
58% of patients with medically intractable temporal lobe epilepsy became seizure-free 
one year after anterior temporal lobectomy together with removal of hippocampus and 
amygdala, compared with only 8% for those who continued to have medical treatment 
alone (Wiebe et al, 2001). Although the procedure has low mortality and morbidity, it 
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is invasive with possible negative sequelae on memory function (Martin et al, 2002). 
When it is not possible to remove the presumed epileptogenic focus or foci, palliative 
procedures such as hemispherectomy, corpus callosotomy, or multiple subplial 
transaction, may be performed to disrupt the pathways important for the spread of 
epileptiform discharges in order to reduce the frequency and severity of the seizures.  
 
7.11b  Vagal nerve stimulation 
An alternative to epilepsy surgery is the implantation of a vagal nerve stimulator. This 
is a multiprogrammable pulse generator which delivers intermittent signals of 
electrical current to the vagus nerve (Schachter, 2002). It is thought that with the 
nerve’s extensive projection to the various neuronal network systems, including the 
reticular-activating system, and the diffuse noradrenergic projection system (Henry, 
2002), its stimulation leads to a reduction in seizure frequency and intensity, with a 
few patients becoming seizure-free (Kuba et al, 2009).  
 
 
7.11c  Ketogenic diet 
The ketogenic diet is a restrictive high-fat, low protein and very low-carbohydrate diet 
mostly given to children (aged 5-10 years) with a variety of medically intractable 
seizure types (Levy and Cooper, 2003). There is much less experience to guide its use 
in younger children, adolescents, or adults. How it acts to suppress seizures is unclear, 
but the diet mimics the biochemical changes associated with starvation, thus creating 
ketosis (Hartman et al, 2007). The ketogenic diet is also effective in patients with 
deficiency of the glucose transporter, GLUT1. It has recently been found that 12% of 
children with early-onset absence epilepsy have GLUT1 mutations, and this may be a 
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mechanism by which the diet has efficacy in these patients (Suls et al, 2009). 
Adherence may be difficult, but in a recent randomised, controlled trial of 147 
children with refractory epilepsy, the mean percentage of baseline seizures was 
significantly lower in the diet group than in controls (Neal et al, 2008). 
 
7.11d  Strategies in development 
A number of innovative techniques are currently being developed to overcome 
treatment resistance in patients with refractory seizures. These include the discovery 
of novel drug targets, new drug delivery systems (Stein et al, 2000), electrical brain 
stimulation (Boon et al, 2007), automated seizure detection and predication (Fountas 
et al, 2005), cell transplantation (Chu et al, 2004), and gene therapy (Raol et al, 
2006). 
 
7.12  Antiepileptic drug polytherapy audit 
To gain more information on combination regimens in patients registered with the 
Epilepsy Unit, an audit was performed to explore polytherapy outcomes in 2881 
patients taking more than one AED (Stephen and Brodie, 2002 - Paper ii). Of these, 
1617 (56%) were seizure-free for over one year, with 332 (21%) taking more than one 
AED.  Effective combinations comprised 40 different duotherapies, 28 triple 
therapies, but only three patients took four AEDs. It was concluded that treatment 
with two or three, but not four AEDs, may be a useful therapeutic option for patients 
not responding to monotherapy. Because this was a retrospective analysis of newly 
treated patients and those with refractory epilepsy, the analysis was subject to bias. 
Lack of a control group was also a weakness. Epilepsy Unit staff are therefore now 
examining similar outcomes in a large population of newly treated patients only. 
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7.13 Outcomes with adjunctive topiramate in refractory epilepsy 
Topiramate can be prescribed as add-on and monotherapy in adults and children with 
partial-onset, myoclonic and generalised tonic-clonic seizures, and as adjunctive 
treatment of seizures associated with Lennox Gastaut syndrome. Shortly after the drug 
gained a UK licence, colleagues at the Western Infirmary Epilepsy Unit undertook a 
prospective study, to gain information on its efficacy and tolerability in a patient 
population with refractory localisation-related and idiopathic generalised epilepsies, in 
the everyday clinical setting (Stephen et al, 2000 - Paper iii).  
 
Topiramate is a sulphamate-substituted monosaccharide which exhibits its 
pharmacological properties via blockade of sodium channels, attenuation of kainate-
induced responses, and enhancement of gamma aminobutyric acid (GABA)-mediated 
inhibition (Petroff et al, 1999). There is also inhibition of carbonic anhydrase activity 
(Shank et al, 1994). In regulatory studies, effectiveness was demonstrated as add-on 
(Ben-Menachem et al, 1996) and as monotherapy (Sharief et al, 1996; Faught et al, 
1996; Privitera et al, 1996), in adults with focal-onset seizures. Topiramate was more 
effective than placebo in patients with idiopathic generalised epilepsies (Biton et al, 
1999), and as add-on treatment for children with focal-onset seizures (Elterman et al, 
1999). It is also effective as adjunctive therapy for seizures associated with Lennox-
Gastaut syndrome (Sachdeo et al, 1999), and may be useful for infantile spasms 
(Glauser et al, 1998). When compared with carbamazepine or valproate monotherapy 
in newly diagnosed epilepsy, a daily dose of 100mg or more was as effective 
(Privitera et al, 2003).   
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Topiramate administration has no clinically relevant effect on other AED 
concentrations, but the drug may reduce phenytoin clearance by selective inhibition of 
isoform 2C19 of the cytochrome P450 super family (Sachdeo et al, 2002). Higher 
doses of the drug can reduce the effectiveness of the COCP (Rosenfeld et al, 1997a). 
Enzyme-inducing AEDs, such as phenytoin and carbamazepine, accelerate topiramate 
metabolism, lowering concentrations by around 40%.  
 
For the purposes of this project, patients were categorised as having refractory 
epilepsy if they had been having monthly seizures for more than five years despite 
treatment with at least four AED monotherapy or combination regimens. Following a 
three month baseline, topiramate was added to current AED therapy in 170 patients, 
using a standard titration schedule. Doses were titrated until one of four end-points 
was reached: seizure freedom for six months or more, ≥50% or <50% reduction in 
seizure frequency for at least six months compared with baseline, or topiramate 
withdrawal because of lack of efficacy, side-effects, or both.  Seizure freedom for six 
months or more was achieved in 39 (23%) patients, eight on monotherapy. A ≥50% 
reduction in seizure frequency over a six month period compared with baseline, was 
reported in 80 (47%) others. The drug was discontinued in 51 (30%) patients, mainly 
due to fatigue, weight loss and irritability, paraesthesiae, depression and headache, all 
recognised side-effects. Many patients obtained a good response with doses lower 
than those employed in regulatory studies, a not uncommon phenomenon. There was 
a wide variation in dose-response and dose-toxicity relationships, making the use of 
plasma concentration monitoring unnecessary.  
 
 
 78
It is important to recognise that because this observational study was undertaken in 
the routine clinical setting at a single centre, with no control group, this may have 
biased results. As discussed in Chapter 4, however, naturalistic trials are valuable in 
informing practical decision making, once the efficacy and safety of an AED has been 
established in rigorous regulatory randomised controlled studies. Because the study 
involved venesection of patients which would not normally be undertaken as clinical 
practice, the project was defined as research, and thus was submitted for (and 
subsequently granted) local ethical approval. A six month time period on a stable 
topiramate dose was selected, as this is employed in many regulatory studies, and was 
considered to be a reasonable time frame within which to assess drug outcomes. This 
study enabled staff to use topiramate confidently, with the knowledge that therapeutic 
drug monitoring is generally unhelpful. Doses employed were often smaller than 
those in regulatory trials.  
 
 
7.14 Topiramate in patients with learning disabilities and refractory epilepsy 
Given that there are few data on AED treatment in patients with learning disabilities, 
it was decided to assess the impact of topiramate in this population attending the 
Epilepsy Unit (Kelly et al, 2002 - Paper iv). In a pragmatic fashion, adjunctive 
topiramate was started in 64 patients with learning disabilities and refractory epilepsy. 
As patients were already attending the epilepsy service, carers had kept a record of 
seizure frequency over at least the three months prior to the addition of topiramate. 
None of the patients were included in the previous study. End-points were the same as 
those described in Paper iii. Carers were asked to monitor appetite, sleep, alertness 
and behaviour, both before, and after the addition of the drug. Of the patients who 
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participated, 16 (25%) became seizure-free, and 29 (45%) had a ≥50% reduction in 
seizure frequency. A further 10 (16%), who obtained some improvement with 
topiramate, continued treatment. The drug was discontinued in nine (14%) patients. 
Mean carer scores did not worsen with topiramate. This investigation showed 
topiramate to be effective as add-on therapy in patients with learning disabilities, with 
seizure freedom being a realistic goal. 
 
Patients attending the Epilepsy Clinic have a blood sample taken for plasma 
concentration monitoring of valproate, phenobarbital, carbamazepine and phenytoin at 
first visit, when dosing is changed, or if drug adherence is an issue. When the use of 
topiramate was monitored in patients with learning disabilities, only those who were 
venesected for routine monitoring of AED concentrations for these reasons also 
underwent topiramate concentration monitoring. As this involved no extra procedures, 
the project was deemed to be clinical audit rather than research, and thus did not 
require ethical approval. A six month time period on a stable topiramate dose was 
again considered to be a reasonable time frame within which to assess drug outcomes. 
As with the previous study, results may be biased because of the observational nature 
of the project and the fact that there was no control group. Some of the baseline 
seizure recordings were retrospective, as it was not considered practical for certain 
patients with learning disabilities to have unchanged medication for a three month 
baseline period. This will also have introduced bias. Although no significant statistical 
conclusions were drawn from the project, the validity of these would be questionable, 
given its design. 
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7.15 Outcomes with adjunctive levetiracetam in refractory epilepsy 
Levetiracetam can be prescribed as monotherapy and adjunctive treatment for partial 
seizures, with or without secondary generalisation, and for adjunctive treatment of 
myoclonic seizures and primary generalised tonic-clonic seizures. Following its 
licensing, a prospective audit was designed by Epilepsy Unit staff to assess the 
clinical value of the drug (Mohanraj et al, 2005 - Paper v).  
 
Levetiracetam binds to synaptic vesicle protein 2A (Lynch et al, 2004), and its 
mechanisms of action appear different from other AEDs (Klitgaard and Pitkanen, 
2003). Placebo-controlled trials using the drug demonstrated reduction in seizure 
numbers and improved quality-of-life in patients with partial seizures, with or without 
secondary generalisation (Cereghino et al, 2000; Cramer et al, 2000; Shorvon et al, 
2000). As add-on therapy, levetiracetam was efficacious against partial-onset and 
secondary generalised seizures in double-blind, placebo-controlled, add-on trials at 
doses of 1000mg-3000mg daily (Betts et al, 2000; Grant and Shorvon, 2000; 
Chaisewikul et al, 2001; Boon et al, 2002). Levetiracetam monotherapy is more 
efficacious than placebo against refractory partial-onset seizures (Ben-Menachem and 
Falter, 2000), and as effective as sustained-release carbamazepine against partial or 
generalised tonic-clonic seizures in a multicentre, double-blind trial (Brodie et al, 
2007). In a systematic review, the drug had a more favourable ‘responder-withdrawal 
ratio’ than zonisamide or oxcarbazepine for drug-resistant localisation-related 
epilepsies (Marson et al, 2001). Studies have suggested efficacy for absence, 
myoclonic and generalised tonic-clonic seizures (Abou-Khalil et al, 2003; Cohen, 
2003; Kasteleijn-Nolst Trenite and Hirsch, 2003; Krauss et al, 2003; Lagae et al, 
2003). In a prospective multicentre open-label study in 42 patients with epilepsy and 
 81
learning disabilities, adjunctive levetiracetam reduced median seizure frequency from 
baseline levels of 4.3 per week to 2.2 per week for those followed up for 6 months. 
(Beavis et al, 2009).  
 
Levetiracetam is not prone to pharmacokinetic drug interactions. Common adverse 
effects include somnolence, asthenia, dizziness, vertigo and headache. Behavioural 
problems such as anxiety, depression and psychoses have been reported in 7% of 
patients. There are no pharmacokinetic interactions with the drug. Lower doses may 
be needed in patients with moderate to severe renal impairment. 
 
At the Epilepsy Unit, adjunctive levetiracetam was started in 156 patients with 
refractory localisation-related or idiopathic generalised epilepsies following a three 
month baseline, and doses titrated according to clinical need.  End-points were seizure 
freedom for at least six months, ≥50% reduction or <50% reduction in seizures for a 
six month period compared with baseline, or levetiracetam withdrawal due to side-
effects, lack of efficacy, or both. An end-point was reached by all 156 patients, 40 
(26%) of whom became seizure-free for at least 6 months, with 33 (21%) having a 
≥50% reduction in seizure frequency for 6 months, compared with baseline. Of the 
seizure-free patients, 25 (63%) took 1000mg or less of the drug. Patients with 
idiopathic generalised epilepsies fared particularly well, with 8 (40%) becoming 
seizure-free. Levetiracetam was withdrawn in 46 (29%) patients due to adverse effects 
(n=27), lack of efficacy (n=8) or both (n=11). It was concluded that the drug is 
effective against a variety of seizure types, often at low doses.  
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As patients were treated no differently to others attending the clinic, with no 
allocation to intervention groups, the project was categorised as audit, and as such, did 
not require ethical approval. Because this observational study followed up patients 
recruited at a single centre epilepsy clinic in a pragmatic fashion, and there was no 
control group, results are therefore subject to bias. Although no significant statistical 
conclusions were drawn from the project, because of its biased design, these may have 
been difficult to interpret. Patients were followed up for six months on a stable dose 
of levetiracetam. This is a reasonable time period over which to assess the impact of 
the drug, being similar to that used in many regulatory studies. Although response 
may have changed with continued follow-up, it was felt that this would not be 
practical in our patient cohort. 
 
 
7.16 Levetiracetam for people with learning disabilities and refractory epilepsy 
To gain experience with adjunctive levetiracetam in patients with learning disabilities 
and refractory epilepsy in the everyday clinical setting, the drug was assessed in an 
audit undertaken at the Epilepsy Unit (Kelly et al, 2004a - Paper vi). Levetiracetam 
was added to AED regimens of 64 patients after a three month baseline, during which 
carers kept a record of seizure frequency. Doses were then adjusted in response to 
seizure frequency and tolerability. Patients were different to those included in the 
previous study with levetiracetam. End-points were seizure freedom for six months or 
more, ≥50% or <50% reduction in seizure frequency for at least six months compared 
with baseline, or discontinuation of levetiracetam due to adverse effects, lack of 
efficacy, or both. Caregivers were asked to assess the person’s sleep, appetite, 
alertness and behaviour whilst taking the drug.  
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Of the cohort, 24 (38%) became seizure-free, and 18 (28%) had an improvement in 
seizure frequency. A marginal benefit was obtained in 8 (12%) patients. 
Levetiracetam was discontinued in 14 (22%) patients because of worsening seizures 
(n=6), lack of efficacy (n=1), or adverse effects (n=7). Caregiver scores were 
‘improved’ at the end of follow up (p<0.001). These outcomes have given Epilepsy 
Unit colleagues valuable experience in using levetiracetam in people whose seizures 
are often perceived to be refractory. Many patients’ seizures became controlled, with 
the majority benefiting from the addition of the drug. As an additional benefit, 
levetiracetam may have improved quality-of-life. 
 
As with the preceding studies, findings from this project would have been enhanced if 
there had been comparison with a control group, although it was felt that use of a 
control group may have led to difficulties if relatives and carers perceived a lack of 
intervention. The small number of patients and the fact that outcomes were derived 
from a single centre may also have biased results. On occasion, some of the baseline 
seizure recordings were retrospective, given the difficulties in obtaining such 
recordings in this patient group. This may also have introduced bias, and made any 
statistical results difficult to validate. More detailed quality-of-life measures may have 
given greater insight into any effects derived from levetiracetam. It was decided to opt 
for a simple likert scale, as this was thought to be easier to use in the routine clinical 
setting. Because patients were managed in the same way as those routinely attending 
the epilepsy clinic, apart from the administration of a simple questionnaire, this study 
was categorised an audit, and thus did not require ethical approval.  
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8. Outcomes in different patient sub-groups with epilepsy 
The management of people with seizure disorders can be complicated. As well as 
taking into account the varying properties of available AEDs, the circumstances of the 
patient are of paramount importance. Age, gender, seizure type or syndrome, lifestyle 
factors, fertility, comorbidity, and comedication all play a crucial role.  For these 
reasons, it was decided to investigate outcomes in teenagers (Stephen et al, 2003 - 
Paper vii), people with learning disabilities (Kelly et al, 2004b - Paper viii), and 
elderly patients (Stephen et al, 2006 - Paper ix) referred to the Epilepsy Unit.  
 
 
8.1 Teenagers 
Epilepsy is the commonest neurological condition to affect adolescents (Wheless and 
Kim, 2002), occurring in more than 60 in 100,000 young people (Hauser, 1992). The 
teenage years can be a difficult time to be given the diagnosis of epilepsy. The 
emotional upheaval of adolescence with its attendant pressures may lead to difficulties 
in accepting the diagnosis and adherence with medication. Assessment of seizure 
activity can be complicated by experimentation with alcohol, and drugs, and sleep 
deprivation. Epilepsy is associated with school absenteeism, and impacts on travel 
opportunities and future employment (Baker et al, 2008). Adolescents can present 
with poorly controlled primary generalised, or partial-onset seizures, which arose in 
childhood. Teenage years are a time when idiopathic generalised epilepsies are likely 
to manifest (Brodie and French, 2000). Photosensitive seizures are also commoner at 
this time of life. There have been recent advances in the understanding of genetic 
abnormalities, leading to some juvenile epilepsy syndromes.  
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History taking can be challenging in adolescents, and is improved by establishing a 
rapport and winning the patient’s trust. Help can be gained from a witness, who may 
provide objective evidence of seizure activity. As with adults, EEG can aid 
classification of seizure type or syndrome, and MRI is the imaging procedure of 
choice (King et al, 1998). A wide range of pharmacological options is now available 
for treatment of epilepsy in this population. Epilepsy surgery can produce excellent 
results in selected young people with drug-resistant epilepsies (Cossu et al, 2008). 
 
In 1996, a nurse-led clinic for adolescents was established at the Epilepsy Unit. As 
there are few published reports on outcomes in this population, a retrospective audit 
of all patients referred over the first four years was performed (Stephen et al, 2003 - 
Paper vii). A total of 301 adolescents were seen, 135 (45%) of whom did not have 
epilepsy, including five taking AEDs. A single seizure occurred in another 22 (7%). 
Of the 144 patients with epilepsy, 76 (53%) were taking AED treatment and 68 (47%) 
were newly diagnosed. Neuroimaging was abnormal in 27 (43%). Following 
pharmacological intervention, >1 year’s seizure freedom was achieved by 76 (53%) 
patients. Of these, four (5%) remained seizure-free off medication. Seizures continued 
in 52 (36%) patients. Another 16 (11%) were lost to follow-up. Prognosis was better 
for newly diagnosed, than for treated epilepsy (59% versus 47% seizure-free; p<0.05), 
and for primary generalised, than focal-onset seizures (60% versus 46% seizure-free; 
p<0.02). It is recognised, however, that this was a retrospective analysis with no 
control group, and thus the biased results may invalidate some of the statistical 
conclusions reached. 
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These poor outcomes prompted a service review, and a new clinic for teenagers 
attending the Epilepsy Unit is currently being instituted. This will include a liaison 
programme with the local children’s hospital, with on-site medical, nursing and 
psychologist staff. One of the aims of the new programme is to randomise patients to 
standard care, or to be managed by the new clinical team.  
 
8.2 People with learning disabilities 
Epilepsy is common in people with learning disabilities. Seizures have been reported 
in 25-40% (Sunder, 1997; McDermott et al, 2005), with the prevalence rising to 50% 
for institutionalised patients (Coulter, 1993). The more profound the disability, the 
more likely the person is to have epilepsy (Gillberg and Soderstrom, 2003). Obtaining 
an accurate history can be problematic, as difficulties with communication are 
common, and these individuals often present with multiple seizure types (Hannah and 
Brodie, 1998a).  Intolerance of investigations, comorbidities, behavioural factors, 
psychiatric disorders, concomitant medication, and difficulties with AED adherence 
and formulations can complicate diagnosis and management (Hannah and Brodie, 
1998b).  
 
Uncontrolled seizures and resultant injuries can impair quality-of-life with carers 
(Espie et al, 1998) and patients having concerns about the sequelae of seizures, the 
consequences of taking AEDs, and social attitudes (Watkins et al, 2006). Outcomes 
are commonly perceived to be poor (Kerr and Espie, 1997), and those affected are 
more likely to suffer ill health (Morgan et al, 2003). There is a lower likelihood of 
seizure remission than in the general population with epilepsy (Sillanpää et al, 1998). 
In a study in 40 general practices, of 318 adults with learning disabilities 58 (18%) 
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had epilepsy. Of these 26% were seizure-free, but 34% had extremely poor seizure 
control (Matthews et al, 2008).  
 
Mortality rates are higher in people with learning disabilities and epilepsy than in the 
general population (Klenerman et al, 1993). There is a higher incidence of seizure-
related death, in particular, SUDEP, than in those without learning disabilities 
(Walczak et al, 2001; Tellez-Zenteno et al, 2005; Hughes, 2009). Of 310 pupils with 
severe epilepsy and learning difficulties attending a residential school, 14 of 28 deaths 
over a 23 year period were attributed to SUDEP, the incidence being 1:295/year, 
compared to a population-based incidence of 1:1000/year (Nashef et al, 1995). In a 
long-term residential care setting, SUDEP was the cause of death in 6% of 113 deaths 
during an 11 year period (Klenerman et al, 1993). When incidence of sudden death 
was examined in patients with learning disabilities with (n=180) and without epilepsy 
(n=125) at a residential facility, the rate was significantly higher at 3.6 per 1000 
patient years in the epilepsy group, compared with 1.3 per 1000 patient years in the 
non-epilepsy group (McKee and Bodfish, 2000). Of the 55 deaths in the epilepsy 
group, 11 (20%) were attributed to SUDEP. Poorly controlled seizures are thought to 
be a risk factor (Hitiris et al, 2007), as well as non-ambulatory status, although the 
latter may be an indirect cause, being a marker of increased susceptibility to morbidity 
(McKee and Bodfish, 2000). Patients with learning disabilities are also at increased 
risk of cardiovascular and pulmonary disease (Patja et al, 2001), and evidence 
suggests that some cases of SUDEP may have an underlying cardiac (Dasheiff and 
Dickinson, 1986; Howell and Blumhardt, 1989; Tavernor et al, 1996; Opherk et al, 
2002; Rugg-Gunn et al, 2004) or respiratory cause (Terrence et al, 1981; Morentin 
and Alcaraz, 2002). 
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There are few randomised double-blind, placebo-controlled AED studies in people 
with learning disabilities and epilepsy. There are three notable exceptions.  Motte and 
colleagues (Motte et al, 1997) studied, in double-blind fashion, the effects of 
adjunctive lamotrigine in 169 children and adults with Lennox Gastaut syndrome. The 
median reduction in seizure count from baseline for those taking lamotrigine (32%) 
was significantly greater than for placebo (9%). Statistically more lamotrigine-treated 
patients had a reduction of at least 50% in the frequency of all major seizure types. 
Sachdeo and co-workers entered patients with learning disabilities into a multicentre 
double-blind placebo-controlled trial of topiramate (Sachdeo et al, 1999). Of the 98 
children and adults who participated, there was a significant reduction in drop attacks 
and tonic-clonic seizures with topiramate, compared to placebo. Kerr and co-workers 
also compared topiramate with placebo in this population (Kerr et al, 2005). 
Topiramate reduced seizure frequency by 30% compared to a 1% improvement with 
placebo, but because of low recruitment, analyses were underpowered. 
 
In a randomised multicentre open-label study, Crawford and colleagues compared 
gabapentin with lamotrigine in 109 patients with learning disabilities (Crawford et al, 
2001). No statistical differences in seizure frequency were found, although when 
carer-rated visual analogue scales were analysed for seizure severity, attention, 
general health and sleeping pattern, patients taking gabapentin had significantly 
improved in all, whereas those taking lamotrigine had improved seizure severity only.  
 
As discussed in Chapter 7, Beavis and colleagues explored the response to adjunctive 
levetiracetam in 42 patients with epilepsy and learning disabilities in a prospective 
multicentre open-label study (Beavis et al, 2009). Recruitment and retention were 
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low. Median seizure frequency reduced from baseline levels of 4.3 per week to 2.2 per 
week for those followed up for 6 months.  
 
It has been shown that a systematic approach to epilepsy management in people with 
learning disabilities can yield benefits (Whitten and Griffiths, 2007). Although 
modern treatment strategies strive for monotherapy, at least 40% of learning disabled 
patients with epilepsy take more than one AED (Hogg, 1992; Singh and Towle, 
1993). Using AED treatment, improvement in seizure control can be seen in people 
with all degrees of learning disability (Huber et al, 2007; Beavis et al, 2007). 
However, patients with milder intellectual problems tend to have better outcomes than 
those with more profound disability (Huber et al, 2005).  
 
Because of the unique issues involved in the management of this patient group, an 
audit of prospective outcomes in 214 people with learning disabilities and epilepsy, 
newly referred to the Western Infirmary Epilepsy Unit over a four year period, was 
performed (Kelly et al, 2004b - Paper viii). Median duration of follow-up was 18 
months (range 13-36 months). It was found that 17 (8%) patients had non-epileptic 
attacks only, 10 of whom were being treated with AEDs. The remaining 197 (92%) 
had epilepsy, the majority (n=151, 77%) presenting with focal seizures. A total of 22 
patients were started on AED treatment, with seizure freedom for at least one year 
being achieved in 10 (45%). AED manipulation was undertaken in a further 136 
patients, resulting in 59 (43%) becoming seizure-free. No relationship was found 
between extent of learning disability and seizure control. There was no deterioration 
in mean caregiver scores rating sleep, appetite, alertness and behaviour. This is 
perhaps surprising, given that patients were started on an additional 54 AEDs during 
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the course of follow-up, and that AED burden has been associated with deterioration 
in quality-of-life in these patients (Pellock, 2002). Results are, perhaps, a reflection of 
the impact of improved seizure control on both patients and carers. It may also be that 
use of novel AEDs, some of which have a lesser propensity for drug interactions than 
more traditional agents, together with the judicious use of AED doses and 
combinations, reduced the likelihood of unwanted effects. Because patients were 
managed routinely, and the only intervention was a simple questionnaire, the project 
was categorised as an audit and did not require ethical approval. 
 
Although study findings would have been strengthened by the use of a control group, 
given the complex issues surrounding the management of epilepsy, and assessment of 
outcomes in this population, it can be particularly difficult to assign patients to 
different interventions. It was decided, therefore, not to proceed with this strategy. 
The study design may have biased results, and although no statistically significant 
conclusions were reached, analyses would have been difficult to interpret accurately. 
Results from this audit suggest AED therapy can result in seizure freedom in more 
than 40% of learning disabled people with epilepsy, without producing unacceptable 
toxicity.  
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8.3 Elderly People 
Old age is the commonest time to develop seizures (Hauser, 1992). As the global 
elderly population grows year by year, so does the number of senior citizens with 
epilepsy. It has been estimated that at this time of life, the annual prevalence of the 
condition is 1%, with an incidence of 134 per 100,000 (Sander et al, 1990). About 10-
30% of these patients will present with tonic-clonic status epilepticus (DeLorenzo et 
al, 1996).  Older people who present with a single seizure are also more likely than 
younger adults to reseizure (Hopkins et al, 1988). Despite these statistics, access to 
epilepsy services is adversely associated with increasing age (Stolarek et al, 1995), 
and under- and mis-diagnosis of the condition is common. The situation is 
compounded further by a paucity of good clinical studies in elderly people. Care of 
these patients will place a growing burden on healthcare services. 
 
Epilepsy can have a profound physical and psychological impact in old age (Baker et 
al, 2001). The stigma of the diagnosis can be hard to deal with at this time of life. The 
unpredictable nature of seizures may lead to social withdrawal. Loss of confidence 
and reduced independence can result in premature admission to care homes. Elderly 
people can be particularly vulnerable to physical injury sustained through seizures. 
Quality-of-life may also be affected adversely by the loss of a driving licence which 
may never be recovered. The situation can be complicated by a range of 
neurodegenerative, cerebrovascular and neoplastic comorbidities, and problems with 
concomitant medication are common (Bergey, 2004). Mortality in elderly people with 
epilepsy is high (Luhdorf et al, 1987), as are rates of SUDEP (Jallon et al, 1999).   
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Because of a relative paucity of randomised double-blind controlled trials of AEDs in 
elderly patients, choice of AED for older people is often based on evidence derived 
from studies in younger adults (Stephen and Brodie, 2000). There are three 
exceptions. Brodie and colleagues randomised newly diagnosed older patients to 
receive lamotrigine to carbamazepine in a 2:1 ratio over at least 24 weeks (Brodie et 
al, 1999). A significantly smaller percentage of patients discontinued treatment with 
lamotrigine (18%) than carbamazepine (42%), due to side-effects. Over 40 weeks, 
Saetre and co-workers randomised newly diagnosed elderly people to receive 
lamotrigine or carbamazepine (Saetre et al, 2007). There was no significant difference 
in seizure-free rates or tolerability between the two drugs. The US Veterans 
Administration Study was an 18 centre, randomised, double-blind double-dummy, 
parallel investigation of 593 senior subjects with newly diagnosed seizures (Rowan et 
al, 2005). The primary outcome measure was 12-month retention in the trial. Early 
termination, mainly due to adverse events, was reported for 44% of lamotrigine-
treated patients, 51% of patients taking gabapentin and 64% of those prescribed 
carbamazepine (p=0.0002). There was no significant difference in seizure control 
between treatment groups. From these three studies, it appears that the major 
difference between newer and established AEDs in elderly people may be tolerability, 
assuming equivalence in dosing. 
 
Given the relatively few publications which concentrate on epilepsy in elderly people, 
outcomes were explored in an retrospective audit of 117 older patients (67 men, 50 
women; aged 65-92 years) in whom partial seizures were diagnosed, and treatment 
begun at the Western Infirmary Epilepsy Unit over a twenty year period (Stephen et 
al, 2006 - Paper ix). Of these, 73 (62%) became seizure-free for at least 12 months on 
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their first AED, with 30 (26%) failing to respond, and 14 (12%) not tolerating initial 
treatment. Following pharmacological manipulation, 93 (79%) patients attained 
remission, 87 (93%) on monotherapy and 6 (7%) on duotherapy. Seizure freedom was 
achieved with the initial AED in 73 (62%) individuals. No individual AED was more 
likely to confer seizure freedom than any other. Patients attaining remission were 
more likely to have had fewer pre-treatment seizures (p=0.0078) than those who did 
not obtain full seizure control. It was concluded that the prognosis for epilepsy in later 
life may be better than in younger people, perhaps reflecting lower lesional 
epileptogenicity and genetic predisposition. Given the retrospective nature of this 
analysis, and the lack of a control group, the results are, however, subject to bias. This 
may throw into question any statistical outcomes. 
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9. Antiepileptic drugs and adverse effects 
Problems with AED tolerability limit the potential for optimal seizure control in 
certain patients. This is despite similarity in efficacy for major seizure types (SIGN, 
2003). Adverse effects are common and are more likely to be associated with AED 
polytherapy (Moran et al, 2004). Of 509 Italian patients, 157 (79% taking 
polytherapy) reported 232 adverse events (Collaborative Group, 1986). When 
questioned at an epilepsy clinic, 134 of 767 adults and children had 155 adverse 
effects (Buchanan, 1992). The AEDs implicated in order of frequency were 
phenytoin, sodium valproate, carbamazepine, clonazepam, barbiturates, vigabatrin, 
and clobazam.  
 
Adverse drug reactions can generally be thought of as pharmacology-related or 
idiosyncratic (Zaccara et al, 2007). Idiosyncratic reactions have been discussed 
previously in Section 5.4. Pharmacology-related effects are a consequence of the 
known pharmacological actions of a drug, and are usually predictable and relatively 
common. They are more usual at the start of treatment or dose increase, and can 
mainly be reversed by dose reduction or drug withdrawal. When starting AED 
treatment, a patient should be informed of associated risks. Many adverse effects 
become apparent within days or weeks, and may be minimised by starting with a low 
dose, and a slow titration schedule. Plasma concentration monitoring can be useful to 
this end.  
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9.1 Central nervous system effects 
AEDs are commonly associated with CNS effects. Cognitive impairment is not 
infrequent in patients with epilepsy, particularly in those with focal epilepsies 
(Dodrill, 1992). Of the established AEDs, phenobarbital perhaps has the greatest 
potential for cognitive and behavioural toxicity. Dose-related impairment occurs in 
attention and vigilance, reaction time, short-term memory, and performance IQ 
(Camfield et al, 1979; Sulzbacher et al, 1999). Phenobarbital may also produce 
hyperactivity, and aggravation of behavioural disorders. Phenytoin can cause a 
decline in concentration, memory, mental speed, visuomotor functions, and 
intelligence (Gillham et al, 1988). The adverse cognitive and psychomotor effects 
found with carbamazepine are likely to be caused partly by the active metabolite 
carbamazepine-epoxide (Gillham et al, 1988; Gillham et al, 1990).  
 
When studied in older patients, valproic acid generally had minimal cognitive impact 
(Craig and Tallis, 1994; Prevey et al, 1996; Read et al, 1998), although the drug 
occasionally can impair attention, visuomotor function, complex decision making, and 
psychomotor speed. Some patients develop a dose-related fine hand tremor (Hyman et 
al, 1979), or reversible parkinsonism (Armon et al, 1996) with valproic acid. 
Comparing the cognitive effects of carbamazepine, phenobarbital, phenytoin, and 
primidone, the Veterans Administration Cooperative study found few pre- to post-
AED treatment neuropsychological changes in patients with new-onset epilepsy 
(Mattson et al, 1985). A second Veterans Administration study found mild cognitive 
changes using carbamazepine and valproic acid monotherapy in the initial treatment 
of partial-onset seizures, although there were no significant differences between the 
two drugs (Prevey et al, 1996). 
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Some of the newer AEDs with multiple mechanisms of action have a poorer 
neuropsychiatric profile than drugs which block voltage-dependent sodium channels 
such as phenytoin, carbamazepine, oxcarbazepine, and lamotrigine. Vigabatrin has 
been associated with agitation, ill-temper, disturbed behaviour and depression 
(Levinson and Devinsky, 1999). Levetiracetam can increase irritability in some 
patients (Mula et al, 2003), although others may experience positive behavioural 
effects (Bootsma et al, 2008). Depression may be more common with this AED 
(Brodie et al, 2007). Topiramate produced somnolence, slowing, memory problems, 
and language difficulties in clinical trials (Ben-Menachem et al, 1996). When the 
cognitive effects of levetiracetam and topiramate were compared in patients with 
refractory epilepsy, no significant differences were found between the two drugs 
(Huang et al, 2008). Lamotrigine has mood stabilising properties as adjunctive and 
monotherapy in patients with bipolar depressive disorder (van der Loos et al, 2009; 
Geddes et al, 2009). Compared to levetiracetam, lamotrigine significantly improved 
anger-hostility subscale scores as add-on therapy in patients with partial seizures 
(Labiner et al, 2009). Zonisamide may impair learning (Berent et al, 1987) and has 
been associated with depression or psychosis in some patients (Miyamoto et al, 2000). 
A few patients taking each of these drugs have developed paranoid and psychiatric 
symptoms, although this seems most likely to occur in patients treated with topiramate 
(Fritz et al, 2005; Meador et al, 2005). 
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9.2 Bone abnormalities 
Bone disease is common in people with epilepsy, and a reduction in bone mineral 
density occurs more frequently in people taking long-term AEDs for epilepsy than in 
the normal population (Souverein et al, 2006). Osteoporosis affects up to 40% of 
women and 12% of men in the Western world (Kanis et al, 1997). The resultant 
morbidity and mortality are associated with major public health and economic 
implications (Walker-Bone et al, 1998). The situation is not straightforward, however, 
as evidence supporting the deleterious effects of AEDs on bone mineral density is 
sparse and conflicting (Boglium et al, 1986; Timperlake et al, 1988; Bauer et al, 
1993; Valimaki et al, 1994; Chung and Ahn, 1994; Sheth et al, 1995). Poor bone 
mineralisation can occur when physical activity is limited by focal neurological 
deficits or cerebral palsy. Institutionalised patients are at an increased risk (Swanton et 
al, 2007). Fear of precipitating seizure activity can lead to restriction of physical 
exercise, and a more sedentary existence (van Linschoten et al, 1990; Gates and 
Spiegel, 1993; Wong and Wirrell, 2006). Lifestyle factors such as smoking, chronic 
disease, concomitant medication, and a family history of osteoporosis, all make the 
condition more likely.  
 
Phenobarbital, primidone, phenytoin and carbamazepine increase the breakdown of 
vitamin D, leading to secondary hyperparathyroidism, osteomalacia and increased 
bone turnover, although not all studies back such a hypothesis (Farhat et al, 2002). 
Other mechanisms include a direct effect of AEDs on osteoblasts, osteocytes and 
osteoclasts, resistance to parathyroid hormone, inhibition of calcitonin secretion, and 
impaired calcium absorption (Fitzpatrick, 2004). Phenytoin may inhibit vitamin K 
metabolism, leading to bone turnover problems (Scott et al, 1987; Vernillo et al, 
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1990). Research has shown an association between elevated homocysteine, reduction 
in bone mineral density, and increased fracture incidence (Elliot et al, 2007). In all, 
six AEDs (phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine, 
lamotrigine) have known anti-folate properties, and thus the potential to increase 
homocysteine concentrations.  
 
In view of this information, a case-controlled study was conducted to explore the 
relationship between bone mineral density and long-term AED treatment in 78 older 
adults (47 women; 31 men, aged 47 to 76 years) treated with hepatic enzyme inducing 
or non-inducing AEDs (Stephen et al, 1999 - Paper x). Each was matched with a non-
epileptic control for age, sex, height and weight. Controls were derived from a 
database of values from normal volunteers recruited following an advert. They had no 
known health problems and were not taking any AEDs, or drugs known to predispose 
to osteoporosis. Patients and controls underwent bone densitometry at the lumbar 
spine and femoral neck, and had blood sampling and urine collected for a range of 
bone markers.  
 
The results showed men had significantly lower bone mineral density compared to 
controls at the lumbar spine (p<0.01), and neck of femur (p<0.005). Women had 
statistically reduced bone mineral density at the femoral neck (p<0.05) only.  The 
influence of enzyme inducing versus non-enzyme inducing AEDs was assessed by 
multiple regression analysis. No significant influence on femoral bone mineral density 
was seen with either subtype. Similar results have since been reported by other 
researchers (El-Hajj Fuleihan et al, 2008, Ensrud et al, 2008). This suggests that 
although hepatic enzyme induction is associated with increased breakdown of vitamin 
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D (in this study, mean serum vitamin D concentrations were significantly lower in 
patients taking enzyme inducing AEDs compared to those on non-enzyme inducing 
agents), and increased bone turnover, this mechanism alone is not responsible for the 
reduction in bone mineral density associated with AED treatment.   
 
It was concluded, therefore, that long-term AED treatment is an independent risk 
factor for reduced bone mineral density in people with epilepsy. All patients with 
bone pathology were prescribed appropriate treatment in the form of vitamin D, 
biphosphonates and calcium. Epilepsy Unit staff now give dietary and lifestyle advice 
routinely, and offer bone densitometry to patients at risk of developing osteoporosis.  
 
 
9.3 Soft tissue and muscle changes 
Chronic dosing with phenytoin can produce gum hypertrophy (Angelopoulos and 
Goaz, 1972), which is minimised with continuing attention to dental hygiene. Long-
term treatment with phenobarbital may be associated with a range of fibrosing 
disorders such as reflex sympathetic dystrophy, shoulder-hand syndrome, frozen 
shoulder and Dupuytren’s contracture (Falasca et al, 1994). 
 
 
9.4 Metabolic effects 
Over the past twenty years, it has come to light that some people with epilepsy may 
have hormonal and metabolic abnormalities (Rasgon, 2004). The effects of seizures 
and AEDs on metabolism are complicated, and have been difficult to assess in a 
variety of studies due to differences in sample sizes, and variability in methodology 
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(Meo and Bilo, 2003). Weight gain has been associated with sodium valproate 
(Dinesen et al, 1984), vigabatrin (Chadwick, 1999), gabapentin (De Toledo et al, 
1997), and pregabalin (Brodie et al, 2005). Conversely, treatment with topiramate 
(Ben-Menachem et al, 1996) and zonisamide (Schmidt et al, 1993) may result in 
weight loss in some patients. 
 
There has been a particular interest in the relationship between polycystic ovarian 
syndrome (PCOS) and epilepsy. PCOS has been defined as the presence of ovulatory 
dysfunction (i.e. menstrual irregularity), hyperandrogenism, or clinical evidence of 
hyperandrogenism and the exclusion of other endocrine diagnoses (Zawadski and 
Dunaif, 1992). Changes associated with PCOS occurred in up to 64% of Finnish 
women taking valproic acid (Isojärvi et al, 1993; Isojärvi et al, 1996). Indian 
researchers reported weight gain (40%), hirsutism (20%) and PCOS (20%) in 25 
women taking valproic acid for one year (Prabhakar et al, 2007). Similar results were 
reported in a Korean study, affecting 42% of women (Kim and Lee, 2007). In other 
studies, PCOS has been found in 7.7% (Luef et al, 2002a), 9.1% (Luef et al, 2002b), 
11.1% (Bauer et al, 2000), 28% (Betts et al, 2001), and 48.6% (Isojärvi et al, 2001) of 
women with epilepsy. Some researchers report PCOS changes in 5.7% to 16.7% of 
patients with carbamazepine monotherapy (Bauer et al, 2000; Isojärvi et al, 2001; 
Luef et al, 2002b), but not all (Betts et al, 2001). A recent Finnish analysis found 
sodium valproate to be a predictor for development of PCOS and polycystic ovaries, 
as well as hyperandrogenism (Löfgren et al, 2007).  
 
The situation surrounding metabolic influences of AEDs is complex, and not yet 
understood fully. Because research tends to be conducted in small cohorts, with 
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designs which may bias outcomes, results need to be interpreted with caution. 
Epilepsy, itself, may be responsible for endocrine abnormalities (Herzog et al, 1986). 
It has been suggested that hepatic enzyme inducing AEDs accelerate hepatic 
biotransformation, increasing testosterone binding and metabolism, thus reducing 
testosterone concentrations. In men, this mechanism may lead to sexual dysfunction 
(Patsalos et al, 1990). In women, this may account for the discrepancy between 
valproic acid and enzyme inducing AEDs being associated with differing prevalences 
of PCOS (Cramer et al, 2007). Others suggest the weight gain associated with 
valproic acid may be responsible for insulin resistance and resultant endocrine 
changes (Isojärvi et al, 1996).  
 
In an attempt to shed further light on this interesting area, two projects examining the 
effects of sodium valproate or lamotrigine in patients with epilepsy were performed at 
the Epilepsy Unit. The first was a cross-sectional study in 40 men and 36 pre-
menopausal women taking either drug as monotherapy (Stephen et al, 2001b - Paper 
xi). Each had blood sampled for fasting insulin, glucose, cholesterol, triglycerides, 
high and low density lipoproteins, testosterone, dihydroepiandosterone, 
androstenedione, sex hormone binding globulin, luteinising hormone, follicle 
stimulating hormone, and AED concentrations. Free androgen index and body mass 
index were calculated. Of the cohort, only four obese valproate-treated women were 
hyperinsulinaemic (p=0.05); three with abnormal menstrual cycles, and one with 
raised testosterone. Testosterone (p=0.02) and triglyceride (p=0.02) concentrations, 
and the free androgen index (p=0.03), were higher in valproate-treated women, 
compared to those taking lamotrigine. Obese patients of both sexes (p=0.01) and 
valproate-treated men (p=0.03) had higher insulin concentrations. It is conceivable, 
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however, that the positive statistical tests were found as a result of chance, as the 
likelihood of false positive results being found increases with the number of 
comparisons made. If the Bonferroni correction is applied, with 0.05 as the critical 
significance level, and taking into account the 13 different comparisons made, the 
actual critical significance level in this study is 0.0038 (ie 0.05/13). Thus none of the 
results are statistically significant. It can therefore be concluded that there were no 
differences in metabolic indices between patients taking sodium valproate or 
lamotrigine. The study would have been strengthened further by comparison of 
treatment groups with a matched cohort not taking AED therapy.  
 
These findings were corroborated by a randomised, prospective study undertaken in 
225 patients with newly diagnosed epilepsy (Stephen et al, 2007 - Paper xii). The aim 
was to compare the efficacy and tolerability of sodium valproate (n=111) and 
lamotrigine (n=114) monotherapy, and effects of these drugs, on circulating 
androgenic hormones. AED-naïve patients were randomised to receive sodium 
valproate or lamotrigine, with doses titrated according to clinical need. Of patients 
with partial-onset seizures, 81 received sodium valproate and 80 were randomised to 
receive lamotrigine. Of those with idiopathic generalised epilepsies, 30 received 
sodium valproate and 34 received lamotrigine, with numbers of patients with different 
syndromes being too small to warrant analysis of these subgroups. Seizure-free rates 
in both treatment arms were identical at 12 months (47%). There was a trend towards 
superiority for valproate (57% seizure-free) over lamotrigine (35% seizure-free) for 
patients with idiopathic generalised epilepsies (p=0.09), but a converse separation of 
outcomes for localisation-related epilepsies (43% seizure-free with valproate, 53% 
seizure-free with lamotrigine, p=0.24). More patients taking sodium valproate 
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withdrew from the study due to adverse effects (p=0.046), eight on account of weight 
gain. Although some of these patients continued to attend the epilepsy clinic, further 
formal monitoring and data collection were not undertaken after stopping sodium 
valproate. Thus, no conclusions could be drawn as to long-term outcomes in these 
individuals. Neither sodium valproate, nor lamotrigine altered circulating testosterone, 
sex-hormone binding globulin, androstenedione concentrations, nor changed the free 
androgen index at six and 12 months. These results have to be considered together 
with the fact that eight patients withdrew from the valproate arm of the study because 
of weight gain. As the long-term consequences of continued sodium valproate could 
not be monitored in these individuals, hormonal findings may be spurious. It was 
concluded that there is little difference between these agents in terms of efficacy when 
used as initial monotherapy in people with newly diagnosed epilepsy. Lamotrigine 
appeared to be tolerated better.  
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10. Conclusions 
The series of studies presented in this thesis demonstrate how AEDs can be used in 
different populations, taking into consideration beneficial and adverse effects. 
Localisation-related epilepsies are often considered less easy-to-control than 
idiopathic generalised epilepsies. The audit in this volume showed the majority of 
patients with focal-onset seizures became seizure-free for over one year with AED 
treatment. Mesial temporal sclerosis was associated with the poorest outcomes, but 
patients with this diagnosis were controlled with drug treatment. Bias may have been 
introduced, however, given the cross-sectional nature of the audit and the fact that 
outcomes from patients with newly diagnosed and refractory epilepsy were analysed.  
 
Data demonstrate also, that people taking AED polytherapy can gain full control of 
their seizures. Treatment with two or three drugs, but rarely four, was successful, 
although retrospective analysis, lack of control group, and inclusion of patients with 
newly diagnosed and drug-resistant epilepsy may have biased results. Epilepsy staff 
are therefore now examining similar outcomes in a large patient population of newly 
treated patients only. 
 
Given the recent influx of new AEDs, it is important for clinicians to gain experience 
in using these drugs, both singly, and in combination. The publications detailing the 
addition of topiramate and levetiracetam to AED regimens in patients with refractory 
epilepsy, showed these drugs to be effective in everyday clinical practice, often in 
doses lower than those recommended by the manufacturers. Efficacy as monotherapy 
was also achieved. Topiramate plasma concentrations varied widely with different 
doses. Concentration measurement is, therefore, largely unhelpful when using this 
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drug. The observational nature of these single centre audits, and lack of control groups 
may have biased results. 
 
Many patients with learning disabilities have seizures which appear refractory to AED 
treatment. Data presented demonstrate this is not necessarily the case. Careful and 
considered follow-up make seizure freedom a realistic goal, without producing 
unacceptable side-effects. Use of topiramate, or levetiracetam in this population, can 
result in good outcomes. Care-giver scoring suggested quality-of-life may improve in 
the majority of patients started on levetiracetam. Again, bias may have been 
introduced by the observational nature of these single centre audits, and lack of 
control groups. Small patient numbers and retrospective baseline seizure recordings in 
some may also have influenced results. 
 
Epilepsy can strike at any time of life, but the condition may have different influences 
on an individual, depending on when it occurs. Despite this, there are few studies 
examining outcomes in different age groups. Results from the nurse-led teenager 
clinic at the Epilepsy Unit were surprisingly poor, with seizure freedom being 
achieved in just over half of patients started on AED therapy. This has been the 
incentive for the institution of a new service for adolescents, linked with the local 
children’s hospital, and providing medical, nursing and psychological support. 
Pharmacological outcomes in older people with epilepsy were better, given that 79% 
of patients became controlled with drug treatment, the majority on monotherapy. 
Conclusions have to be considered in light of the fact that neither observational audit 
employed a control group and analyses were retrospective. 
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Adverse effects of AEDs are a common clinical problem. The case-controlled study 
presented explored the relationship between long-term AED use and bone mineral 
density, in older adults with epilepsy. AED treatment was found to be an independent 
risk factor for reduced bone mineral density. With the high morbidity and mortality 
associated with osteoporosis, this result has prompted Epilepsy Unit staff to identify 
at-risk patients, and offer appropriate screening and intervention. 
 
The final papers, comparing hormonal outcomes in patients taking sodium valproate, 
or lamotrigine monotherapy, concluded that if any metabolic changes are associated 
with valproic acid, these only affect a minority of people. The case-controlled study 
found significantly higher insulin concentrations in obese people taking sodium 
valproate, but only four obese women had hormonal abnormalities. When results were 
corrected for multiple comparisons, however, no differences in parameters were found 
between sodium valproate and lamotrigine. The randomised, controlled study 
confirmed this, with no significant hormonal differences, or significant differences in 
efficacy, between the two arms. Continued monitoring may have provided further 
valuable information and reduced bias. These results have helped colleagues to 
counsel patients appropriately, when starting these medications. 
 
In recent times, the emergence of new AEDs, and modern investigative techniques 
have revolutionised the management of seizure disorders. This body of work has 
added to current knowledge on outcomes in localisation-related epilepsies, results 
with different polytherapy regimens, the pragmatic utilisation of novel drugs, 
prognosis in different age groups, and adverse effects associated with AEDs. Findings 
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should be considered in the context that the design of several of the projects may have 
introduced inherent bias.  
 
With accurate classification of seizure type or syndrome and timely management, the 
outlook for individuals with epilepsy has never been more positive. In coming years, 
genomic research may shed further light on seizure pathophysiology and the reasons 
underlying refractoriness and adverse drug effects. As such, it is hoped this may allow 
a more precise selection of AED treatment, and greater potential for seizure freedom.  
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